Risk Factors for Gastric Cancer and Risk Stratification in Singapore Chinese Population by ZHU FENG
 
 
RISK FACTORS FOR GASTRIC CANCER AND RISK 







A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
DEPARTMENT OF MEDICINE 
YONG LOO LIN SCHOOL OF MEDICINE 





















My deepest gratitude to: 
Associate Professor Yeoh Khay Guan for agreeing to be my mentor on top of his busy 
schedule. I have learned a lot through our regular research meetings on interpreting 
data, discussion on study design and the implication in the clinic, writing the 
manuscripts.  Being both my mentor of PhD study and the supervisor of the work, his 
influence is not just on the teaching of principle of research but also on the character 
development (be objective, doing the right things and strategy planning).  His patience, 
guidance and encouragement had helped me pass through all the obstacles. I am 
grateful for all the opportunities he has given - exposed me to various international or 
local collaborations and oversea conferences. I have become more and more confident 
to continue on the clinical research. It has been very fortunate to be able to work with 
him in the past years.  
Associate Professor Richie Soong for his guidance in writing the first manuscript and 
his advice on gastric cancer genetics.  
Professor Chia Kee Seng for bringing me in the world of epidemiology and 
encouragement in the PhD study.  
Associate Professor Koh Woon Puay and Professor Yuan Jian Min for the 




Dr Lim Lee Guan and Ms Jennie Wong for their advice on gastroenterology and 
review of manuscript. 
Our great GCEP team, without all of you, we could not carry out our research. A big 
thanks to our lovely research nurses and research coordinators. A special thanks to Ms 




TABLE OF CONTENTS 
Acknowledgements ........................................................................................................................ 1 
Summary  ......................................................................................................................................... 5 
List of Tables ................................................................................................................................... 8 
List of Figures ............................................................................................................................... 10 
Abbreviation  ................................................................................................................................. 11 
Chapter I: Background ............................................................................................................ 12 
Chapter II: Study populations ............................................................................................... 29 
2.1 GCEP ....................................................................................................................................... 29 
2.2 SCHS ........................................................................................................................................ 35 
Chapter III: Feasibility of Endoscopy Surveillance and Risk Factors of Early 
Gastric Neoplasia in a High Risk Cohort  ........................................................................ 39 
Study 1 - Systematic Endoscopic Surveillance in a High-risk Cohort is Feasible for the 
Detection of Early Gastric Neoplasia....................................................................................... 42 
Study 2 - Clinical Risk Factors and Premalignant Lesions of Gastric Neoplasia in High 
Risk Cohort  .................................................................................................................................. 58 
Chapter IV: Study 3 - Genetic risk factors for gastric cancer and premalignant lesion 
of gastric cancer ............................................................................................................................ 67 
Chapter V: Study 4 – Using Pepsinogen and HP antibodies to predict the risk of 
gastric cancer ................................................................................................................................. 83 
Chapter VI: Conclusion and Future Studies .................................................................... 97 
Chapter VII: Reference .......................................................................................................... 104 
4 
 






About one million people are diagnosed with gastric cancer each year worldwide, 
making gastric cancer the 4th most common cancer. Half of the global burden occurs 
in East Asia. Gastric cancer is also the second leading cause of cancer death worldwide 
accounting for 736,000 deaths in 2008. 
The known risk factors for gastric cancer are Helicobacter pylori (HP) infection, diet with 
high intake of salt and preservatives, smoking, alcohol, family history of gastric cancer 
and pernicious anemia. The disease etiology is multi-factorial and genetic risk factors 
are not the main driver, however in association with environmental factors, gene 
polymorphism studies have identified specific genetic susceptibilities predisposing to 
development of gastric cancer (GC).  
Primary prevention is theoretically possible for instance through attempting eradication 
of Helicobacter pylori infection.  Secondary prevention by screening and surveillance is 
practised in Japan and Korea where the population incidence of GC incidence is high. 
Early detection by endoscopy screening and surveillance has been shown to reduce 
mortality rate in Korea. It is thought to be not cost-effective to screen the general 
population in countries with low to intermediate GC incidence rates such as Singapore.  
Endoscopy is the only current technology that allows diagnosis of early GC.  Early 
detection by endoscopy screening is the key to reducing mortality, however it is costly 
and invasive. Risk stratification to identify individuals at high risk of GC is a potential 
method to reduce the cost of screening and surveillance. The gastric carcinogenesis 
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sequence from superficial gastritis to subsequent development of atrophic gastritis, 
intestinal metaplasia, dysplasia and finally culminating in adenocarcinoma is well 
established. People with precursor lesions such as atrophic gastritis and intestinal 
metaplasia are believed to be at higher risk of developing GC.  
This thesis sets out to describe the risk factors for GC in our local population and to 
explore the possibility of stratifying the Singapore Chinese population into those with 
low or high risk for GC based on genetic risk factor and precursor lesions of GC.  
The first two studies (GCEP, described in Chapter III of this thesis) describes a cohort 
of Singapore Chinese subjects recruited for the GCEP study, which aimed to 
determine whether a local programme of systematic prospective endoscopic screening 
is able to detect early GC and/or high grade dysplasia in a high risk Singapore Chinese 
population. In this cohort we studied the clinical risk factors and the prevalence of 
premalignant lesions such as atrophic gastritis and intestinal metaplasia.   
In the third study (Chapter IV), we investigate the presence of gene polymorphisms 
associated with GC risk in subjects with gastric intestinal metaplasia, regarded as a pre-
neoplastic precursor for GC.   
In the fourth study, we evaluate the use of blood markers for predicting GC risk. Since 
Helicobacter pylori (HP) is the most important single risk factor for GC and gastric 
atrophy is a well-established risk factor, we studied the combination of HP antibodies 
and serum pepsinogen (PG) in a serology panel and explored the use of this HP-PG 
panel for risk stratification purposes in our population.  
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The results from these studies suggest that it is possible to risk stratify the Singapore 
Chinese population based on genetic polymorphisms, HP infection and presence of 
atrophic gastritis and intestinal metaplasia. Five clinical risk factors were found to be 
significantly associated with the development of early gastric neoplasia. Three genetic 
polymorphisms in combination with HP infection were found to be useful to identify 
individuals who are more likely to develop IM and therefore GC. Individuals with both 
HP infection and atrophic gastritis as measured by PG index had 14-fold increased risk 
of GC  
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C h a p t e r  I  
BACKGROUND 
1.1 Epidemiology 
Gastric cancer incidence  
Despite falling gastric cancer (GC) incidence rates in most countries, there were still 
about one million new cases diagnosed in 2008, making it the 4th most common 
cancer in the world since 2002 (1, 2). A declining trend in incidences of GC had been 
observed in many countries, including Nordic countries, North American countries 
with low incidence rate and Eastern Asian countries with high incidence rate (Figure 
1.1). GC is more common in the elderly and incidence increases with age (Figure 1.2). 
Males have 2 times higher risk than females.  
As shown in Figure 1.3, Korea has the highest age-standardized incidence rate for 
males in Asia and in the world (62.2 per 100,000), followed by Mongolia (48.2 per 
100,000) and Japan (46.8 per 100,000). China has an incidence rate of 41.3 per 
100,000 for males. Given the size of its population (688 million males in 2011), this 
translates to an estimated 284,468 new male GC cases annually, exceeding that of any 
other Asian countries. The GC incidence rate among females is the highest in Korea, 
Mongolia, and China (24.6, 22.3 and 18.5 per 100,000 females, respectively). In 
comparison, incidence in the United States is much lower with the rate of 2.8 per 
100,000 females (Figure 1.3) (3).  
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In Singapore, GC incidence rate has declined since 1975 but incidence increased 
sharply in people who were age 55 and above (Figure 1.4). Singaporeans of Chinese 
descent, which comprise 70% of the total population, have higher age standardized 
incidence rate than Malays and Indians, and account for 90% of new GC cases every 
year. The age-adjusted relative risk for male and female are all significantly lower in 
Malay and Indian than in Chinese (Table 1.1). The age standardized incidence rate of 
GC for the period 2006 to 2010 is 14.3 per 100,000 per year in Singapore Chinese 
males and 7.9 per 100,000 per year in Singapore Chinese females (Singapore Cancer 
registry). The risk of GC in Singapore Chinese is at intermediate levels, in contrast with 
countries with high GC incidence such as Korea and Japan and low GC incidence 




Figure 1.1 Trends in Incidence of gastric cancer in selected countries 













Figure 1.3 Estimated Gastric Cancer Incidence and mortality Worldwide in 








Figure 1.4 Trends in gastric cancer incidence in Singapore (1968-2002)  
 
 
Table 1.1 Incidence of Gastric Cancer in Singapore among Chinese, Malay and 
Indian (1998-2006) 
Incidence data     Male Female    
(1998-2002)  No.  ASR* RR** No. ASR* RR** 
All Residents  1442 18 - 966 9.9 -  
Chinese  1310 21.4 1 883 10.8 1 
Malay  64 6.6 0.3 41 3.8 0.4 
Indian  61 7.8 0.4 34 6.1 0.6 
 (2002-2006)   
All Residents  1340 14.4 - 863 7.6 -  
Chinese  1200 17 1 798 8.5 1 
Malay  56 5.7 0.3 - - -  
Indian  72 7.7 0.5 27 4 0.5 
*Age standardized incidence rate (to world population) per 100,000/year  
**Age adjusted Relative risk    
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Gastric cancer mortality  
GC is the second leading cause of cancer death in both genders worldwide, 
accounting for 736,000 deaths in 2008 (1). The highest mortality rates were seen in 
Eastern Asia (28.1 per 100,000 in men, 13.0 per 100,000 in women), the lowest in 
Northern America (2.8 and 1.5 respectively). Overall, females are more likely to 
survive GC than males. The survival rate is also related to stage distribution. In the 
United States, the survival rate during the period 2002-2008 was 62% in early stage 
and only 3.7% in metastatic GC (Table 1.2). The survival rate is higher in those 
countries with higher proportion of early gastric cases such as Japan (5). Among  
countries with high incidence rates, Japan has the highest survival for GC (Figure 
1.3). 
Table 1.2 Stage distribution and 5-year survival by stage at diagnosis for 2002-2008, 
based on U.S SEER data 





Localized (confined to primary site) 24 62.3
Regional (spread to regional lymphnodes) 31 27.7
Distant (cancer has metastasized) 34 3.7





1.2 Risk Factors  
GC is a multi-factorial disease with genetic and environmental risk factors. The 
incidence of GC shows geographic variation, time trend and immigration effect. This 
suggests both environmental and lifestyle factors contribute significantly in the 
development of GC.  
Helicobacter pylori infection 
Helicobacter pylori (HP) was recognized in 1994 by the WHO as a class I carcinogen. It 
is one of the most significant environmental risk factors. The risk associated with HP 
was about 2 - 8 fold (6-9).  
The prevalence of HP infection varies in different countries and population and it 
increases with age. In Asia, where the incidence of GC is high, the prevalence of HP is 
also very high. In China, prevalence had been shown to be as high as 92% in cohort 
study population (10). In Japan, it was shown to be around 80% in a few prospective 
cohort studies (11-13). Prevalence of HP in South Korea was reported as about 60% 
(14, 15).  
There are broadly two divergent responses of long-standing HP infection. One is 
antral-dominant gastritis with little atrophy which causes duodenal ulcer and is 
reported to have little risk for GC. The other response is corpus-dominant gastritis 
with multi-focal atrophy which indicates high risk of GC. Research on GC 
carcinogenesis supported HP as carcinogen of GC and it was believed that HP 
triggered the sequential pathologic changes of the gastric mucosa through atrophic 
gastritis, intestinal metaplasia and dysplasia, then carcinoma (16-18). The susceptible 
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host, other environmental virulence factors and duration of HP infection also played 
important roles in HP induced GC.  
A few mechanisms on how the HP infection induced the DNA molecular changes in 
the GC development had been proposed. The leading hypothesis is oxidative stress. 
The HP infection caused production of reactive oxygen and nitrogen species and 
suppresses the host antioxidant defense mechanisms, leading to oxidative DNA 
damage (19). The other mechanisms include 1) HP promotes the formation of 
mutagenic substances through inflammatory mediators (16). 2) HP infection induces 
mutations in the mitochondrial and nuclear and causes DNA damage (20).  3) 
Aberrant DNA methylation induced by HP infection affects the risk of GC (21, 22).  
There are many kinds of HP strains and individuals infected with HP may have more 
than one strain (23-25). Past studies had shown that infection containing virulent 
cagA strains increased the risk of GC (26, 27).  
Although about two thirds of the world population is infected with HP, only 1 in 1000 
HP infected people will develop GC (28). This makes HP eradication not cost-
effective in GC prevention. Studies had also suggested that HP eradication should be 
carried out early because it was only effective before the premalignant lesions 




It is well known that high salt intake increases the risk of GC while high 
consumption of vegetable and fruits protects people from getting GC. Based on a 
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recent meta-analysis of prospective studies, salt intake was shown to be directly 
associated with the risk of GC and the risk increased with increase in the level of 
consumption (32). Other possible dietary risk factors include intake of nitrate, nitrite 
and nitrosamine which are often found in either nature food such as cabbage, 
cauliflower, carrot, celery, radish, beets, and spinach or in preserved food. Based on a 
population study in Japan, isoflavones, which are found in soy food, have a 
protective effect in the development of GC (33).  
Smoking and Alcohol 
 
Smoking had been proven to be associated with the 1.5-2.5 fold increased risk of GC 
in both case-control and cohort studies in different populations. The risk increases 
with the frequency and duration of smoking. In a meta-analysis, the relative risk was 
1.6 in men and 1.1 in women. Two studies (the European Prospective Investigation 
into Cancer and Nutrition study and the Multiethnic Cohort (MEC) Study, in Hawaii 
and Los Angeles) had shown higher hazard ratios (HR) of GC in cardia (HR 2.86-
4.10) than in the distal part of the stomach (HR 1.52-1.94) (34, 35).  
Unlike smoking, results on the association between alcohol and the risk of GC had 
been inconsistent. There are a few possible reasons. First, self-reporting of alcohol 
consumption is unreliable as the measurement of the quantity of alcohol 
consumption is not standardized. Secondly, recall bias in case-control study may 
affect the result significantly. Lastly, alcohol effect may be so small that the effect 
could not be shown in past studies. Recently, two prospective large cohort studies 
reported positive association between alcohol consumption and GC risk. In the 
European Prospective Investigation into Cancer and Nutrition study, heavy 
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consumption of alcohol (>60 g/day) was found to be positively associated with the 
risk of intestinal type non-cardia GC in men with HR (95%CI) 1.65 (1.06-2.58) (36). 
In a population based cohort study in Shanghai, China, heavy drinkers were found to 
have significantly increased risk of GC with HR (95% CI) of 1.46 (1.05-2.04) (37).  
Family history of gastric cancer 
 
People who had family history of GC had been well studied and were consistently 
reported to have increased risk of GC (OR 1.5-3.5) in case-control studies in 
Chinese, Japanese and Korean (38-43). The risk in those with family history of GC 
was reported to be higher in Turkey and India (44-46). It was also higher in those 
with more than one first-degree relative who had GC (43). The positive association 
between family history and GC development may be due to the genetic susceptibility 
and also exposure to the other same risk factors such as HP infection, specific diet 
and smoking. However, the specific genes which elevated the risk of GC in family 
members of GC subjects have not been identified. In order to estimate the real effect 
of familial risk, a large twin study including 44,788 pairs of twins in Scandinavia had 
been conducted (47). In dizygotic twins, the risk of the other twin getting GC when 
one partner has had GC was 6.6 times as high as twins with no partner having GC. 
The risk increased to 10 fold when the twins were monozygotic. The study further 
estimated that the inherited gene contribution was about 28% in the GC 
development, with another 10% contributed by shared environmental risk factors, 
and the remaining 62% contributed by non-shared environmental factors. The study 
confirmed that familial factors play a role in GC development but compared with 




1.3 Pathology  
The stomach can be divided into four anatomic parts: cardia, fundus, body and 
antrum. The cardia is located just next to the esophagus. The fundus is the left upper 
area of the stomach. The antrum is the distal one third of the stomach, and extends to 
the pyloric canal which connects the stomach and the duodenum. The body, which is 
between the fundus and antrum, is the largest part of the stomach.  While the 
incidence rate of GC is declining worldwide, the incidence of gastric cardia cancer was 
reported to be increasing in western countries (48-50). It is believed that cardia cancer 
has different epidemiologic characteristics and risk factors from cancers in other parts 
of the stomach (8, 51, 52). Based on past studies, there were two etiologies for cardia 
cancer (53, 54). In areas where  prevalence of atrophic gastritis caused by HP is high, 
the majority of cardia cancers are related to HP infection, similar to the cancer in other 
parts of stomach (55, 56). However, in western countries where atrophic gastritis is 
rare but gastroesophageal reflux disease is common, cardia cancer is closely related to 
esophagus cancer which is strongly associated with Barrett’s esophagus (57).  
According to WHO classification, gastric adenocarcinoma has four main histologic 
types (58). Tubular adenocarcinoma is the most common one, followed by signet-ring 
cell carcinoma, papillary adenocarcinoma and mucinous adenocarcinoma (59). Based 
on morphological features of the tumors, Lauren classified the gastric adenocarcinoma 
into intestinal type, diffuse type and mixed type(58). Intestinal type adenocarcinoma is 
characterized by gland formation while the diffuse type has little or no gland 
formation. Intestinal type cancer is seen more often in the elder male population with 
premalignant lesions such as atrophic gastritis, intestinal metaplasia or dysplasia (60, 
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61). Diffuse type cancer usually arises from younger population without any 
histologically abnormal background in the stomach (62). It is well known that these 
two types of GC have two different pathways (63). Intestinal type is believed to follow 
the famous stepwise progression which starts from HP infection, progresses to 
atrophic gastritis, intestinal metaplasia, dysplasia and finally to carcinoma in the 
stomach (64). Diffuse type is also associated with HP but without any intermediate 
lesions (65). The studies had shown E-cadherin/CDH1 mutation was one of the 
causes of hereditary diffuse GC (66-68) and indicated that genetic risk factors may play 
an important role in diffuse type GC development.  
1.4 Clinical Diagnosis 
Oesophagogastroduodenoscopy (OGD, endoscopy) and biopsy 
Performing an OGD is the only way to detect early GC. The diagnostic endoscopic 
procedure allows direct visualization and the biopsy of any suspected lesions in the 
upper part of the gastrointestinal tract up to the duodenum.  The device is a flexible 
tube carrying a CCD video-chip in front which relays an image to the viewing screen. 
The sensitivity of OGD is 74-84% (69). New technologies such as chromoendoscopy 
with indigo carmine spray (70, 71), narrow band imaging (NBI) (72-74), 
autoflourescence imaging (AFI) (75) and confocal endomicroscopy (CE) (76, 77) help 
improve the detection rate of cancer or premalignant lesions . OGD has been used as 
the one of main screening tools in Korea since 1999 (78).  




The double-contrast barium study has been widely used for population screening in 
Japan since 1960 (69). It was believed that the population screening has contributed to 
the reduction of the mortality rate of GC in Japan which has dropped significantly 
since the 1980s.  
Computed Tomography  
Computed Tomography (CT scan) is performed for the staging of GC by indicating 
the size of the tumor and location of the tumor (79). The thorax, abdomen and pelvis 
are included to assess distant metastasis and involvement of lymph nodes. However, 
CT scan was found to be not sensitive in detecting peritoneal metastasis (80). 
1.5 Staging 
Staging of GC is the objective evaluation of the stage of development and/or 
metastasis of the cancer (81) (82). The stage of the GC determines the treatment plan 
and the prognosis of the disease. A standardized staging system is also important in 
comparing the treatment outcome in clinical trials or between different centers or 
different countries. The AJCC system (American Joint Commission on Cancer) is 
widely used in western countries as well as some Asia countries (83). Japan has its own 
system in defining GC stages (84). The AJCC system describe 1) the size and depth of 
the tumor in stomach (T); 2) whether the cancer spreads to regional lymph nodes (N); 
3) distant metastasis - whether the cancer spreads to the other organs (M) (82). The 7th 
edition of the AJCC staging system has grouped gastric into IA, IB, IIA, IIB, IIIA, 
IIIB, IIIC and IV based on the combination of tumor, lymph nodes and metastasis 
information (85). The AJCC TNM system has proved to be accurate in the prediction 
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of prognosis (86). Early stage GC was found associated with better survival rate 
compared with late stage GC (87). 
1.6 Treatment 
Surgery is the only curative treatment option for GC (88). The aim of the surgery is to 
remove the tumor and the affected lymph nodes completely. Gastrectomy is indicated 
for stage IB – III when the tumor is locally resectable and has no metastasis.  
Chemotherapy in resectable gastric cancer 
Post-operative (adjuvant) chemotherapy was not part of the standard of care in GC 
patients because most trials failed to show adjuvant chemotherapy improved the 5-year 
survival rate (89-91). However, one recent meta-analysis suggested there was some 
benefit from adjuvant chemotherapy (92).  The Medical Research Council Adjuvant 
Gastric Infusional Chemotherapy (MAGIC) trial (93) compared subjects who were 
given both pre-operative chemotherapy and post-operative chemotherapy with those 
who had surgery alone and showed that subjects who had surgery alone had significant 
survival benefit with chemotherapy. Five-year survival rate was 36% in the 
chemotherapy group compared with 23% in the surgery only group. However, the 
study included 22% esophagus cancer patients. Out of 253 patients who underwent 
surgery alone, only 42% underwent D2 distal dissection or D2 total dissection. More 
randomized trials taking into consideration of types of GC, types of surgery (D1 or D2 
dissection), the local recurrence and the combination of the drugs are needed.  
Chemotherapy in advanced gastric cancer 
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In advanced GC, the main objective is to relieve the symptoms and improve the 
quality of life. Chemotherapy may be offered to extend the lifespan but should be 
balanced by the toxicity of drugs which could affect the patient’s quality of life (94, 
95).  
Endoscopic submucosal dissection (ESD)  
ESD is an endoscopic procedure for removing benign, malignant lesions in 
gastrointestinal tract and has been used widely for the treatment of early GC in Japan 
as the proportion of early GC detected was high(96) (97-99). It is less invasive and is 
able to cure the early GC without removing the stomach. The criteria in applying 
ESD for treatment of early GC are 1) well or moderately differentiate 
histopathology; 2) tumor size ≤3cm; 3) tumor invasion is limited to submucosal 
layer; 4) no lymphatic or vascular invasion (100). ESD was accepted as an efficient 
and easy to use method for the treatment of early GC (101, 102).  
1.7 Prevention and Screening 
GC is a common disease with high mortality rate (1). A high proportion of GC cases 
are detected in late stage because lack of specific early symptoms. Primary prevention 
and secondary prevention are important in reducing the GC incidence and mortality 
rate (103, 104). Primary prevention of GC includes eliminating the common risk 
factors for cancer such as low socioeconomic status, smoking, dietary factors (intake 
of salt and preserved food) (105) and specific risk factor for GC - HP infection (106, 
107). An example of primary prevention is the improvement of socioeconomic status 
caused the decline in GC incidence rates in Singapore since 1970s (108). It was 
around the same period when the Singapore economy grew rapidly with GDP 
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increase between 5-15% every year during the period of 1965-1985 (109). At that 
time, the public housing was initialized and the water supply and sanitation system 
was improved significantly. The usage of refrigerators became popular and it helped 
keep food fresh and reduced the consumption of salted or preserved food.  This may 
help explain the sharp drop in incidence rate since 1970s in Singapore.  
After HP was recognized as group I carcinogen by WHO in 1994, a few randomized 
trials had been carried out to investigate the effectiveness of HP eradication in GC 
prevention (29, 110-112). The sample size of those studies was relatively small. The 
evidence of preventive effect of HP eradication was not significant in overall cancer 
incidence but all of the trials demonstrated the regression of premalignant lesions 
after successful eradication. One of the trials performed in China in 2004 concluded 
that HP eradication reduced GC risk only in subjects who have not developed any 
premalignant lesions (29).  
Avoiding the risk factors help to reduce the risk of developing GC but it cannot 
guarantee that GC will not occur. Early detection by screening as the secondary 
prevention is the best way to find cancer earlier and get cured especially in countries 
with high incidence rate. So far, mass screening was only available in Japan and 
Korea. Japan started population screening for GC using photofluorography (X-ray) 
in the 1960s, and remarkable improvement in survival rates from GC has been 
achieved as a result of early detection and consequently higher cure rates (113, 114). 
A nationwide GC screening program in Korea was initiated in 1999 as part of the 
National Cancer Screening Program (NCSP). The NCSP recommends that men and 
women over 40 years of age undergo GC screening every 2 years, with an upper 
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gastrointestinal series (UGIS) or by endoscopy (115).  The preliminary data 
suggested the participation rate of the screening programme was low and more 
people underwent UGIS than endoscopy (78, 116). The effectiveness and efficacy of 
screening general population with high incidence rate of GC is still unclear.  
In countries with low or intermediate incidence rate for GC, mass screening was not 
cost-effective as the benefit of early detection of a few GC could not offset the cost, 
and the risk of the screening programme caused by screening tests. Pepsinogen had 
attracted more and more attention in identifying people who were at high risk for GC 
as low pepsinogen level indicated the presence of atrophic gastritis which is the 
premalignant lesion for GC. Those identified high risk group would be referred for 
endoscopy screening. In Japan, a few prospective studies had proved that the 
combination of pepsinogen test and HP antibody test could predict GC risk and 
stratify people in low and high risk group for GC. More prospective studies are 
required to assess the effectiveness and efficacy of different screening programmes.  
Screening is the key in early detection of GC to reduce mortality rate but not cost-
effective in countries with intermediate incidence rate like Singapore, we conducted the 
following studies to determine the feasibility of applying targeted screening in the 
Singapore Chinese population by stratification into low or high risk for GC using 
known risk factors or blood markers: 
Study 1 - Systematic endoscopic surveillance in a high-risk cohort is feasible for the 
detection of early gastric neoplasia 




Study 3 - Genetic risk factors for gastric cancer and premalignant lesion of gastric 
cancer 




C h a p t e r  I I  
STUDY POPULATIONS 
The study populations of this thesis are from two data sources: Gastric cancer 
Epidemiology and Molecular Genetics Program (GCEP) and Singapore Chinese 
Health Study (SCHS).   
2.1 Gastric Cancer Epidemiology and Molecular Genetics Program (GCEP) 
The GCEP study is a prospective, multi-center cohort study of subjects who are at 
high risk of developing GC. GCEP was initiated in January 2004 with a planned 
enrolment of 3000 Chinese subjects age > 50 years, offering screening by endoscopy 
with systematic prospective follow-up over a minimum of 5 years. Study sites included 
all four major public hospitals in Singapore – National University Hospital, Tan Tock 
Seng Hospital, Singapore General Hospital and Changi General Hospital. In 
Singapore, 80% of hospitalization and specialist services are provided by public 
hospitals and 20% by private hospitals. Clinical information including demographics, 
medical history and family history were obtained. Informed consent was obtained 
from all subjects and the study was approved by the institutional review boards of all 
hospitals involved. The main outcome measurement is number of subjects who 
develop high grade dysplasia, intramucosal carcinoma or gastric adenocarcinoma. The 
primary objective of the GCEP study is to identify predictive risk factors from a high 
risk cohort and to develop an optimum approach and cost-effective algorithm for 
targeted screening for GC in the Singapore Chinese population. 
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The enrollment of 3000 subjects had been completed in Dec 2010 and the study is still 
in progress. 1300 subjects had completed the minimum 5 years of surveillance and the 
rest will be completed by 2015. Eighteen high grade dysplasia, intramucosal carcinoma 
or adenocarcinoma cases were detected so far with average follow up of 3 years.  
Subject Selection 
A total of 4085 Chinese, age above 50 years, which included patients seen in 
gastroenterology clinics during the period 2004-2010 and referred by the doctors, and 
subjects recruited from public forums. To be eligible, the subjects had to 1)  be 
Chinese; 2) be greater than 50 years; 3) satisfies one or more of the following criteria: 
has (had) a history of dyspepsia of at least 4 weeks or more. Dyspeptic symptoms 
include bloating, epigastric discomfort and early satiety. Has a family history of GC. 
Has a medical condition for which an OGD is indicated. Participation in public forum 
and keen to undergo endoscopy screening. 
The subjects who had bleeding disorders, such as haemophilia, in whom biopsies are 
contraindicated, were excluded from GCEP. The subjects with liver cirrhosis, previous 
total or partial gastrectomy, severe co-morbid illness, such as end-stage renal failure 
(ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA) and rheumatoid 
arthritis (RA) requiring long term non-steroidal anti-inflammatory drug (NSAID) 
therapy, other severe acute or chronic medical or psychiatric condition or laboratory 
abnormality that may interfere with the interpretation of study results. The subjects on 
aspirin, ticlopidine and clopidogrel must be able to undergo a one-week washout 
period before gastroscopy.  
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After interviewing patients and review of patients’ case notes, 3094 Chinese who were 
over 50 years old signed the patient informed consent form and agreed to participate 
in the GCEP study. Reasons of not participating included 1) worrying about the 
discomfort and complications of endoscopy; 2) not willing to give blood; 3) not willing 
to join the research study; 4) medical condition which made one not suitable for taking 
biopsy; 5) having GC in the past. One hundred and nineteen subjects were later 
excluded from the study because they refused to have baseline endoscopy examination 
or no biopsy was taken during baseline endoscopy. 2975 subjects were included in the 
baseline analysis. (Figure 2.1)  
Questionnaires  
At enrolment, all subjects were interviewed by trained research nurses with baseline 
questionnaire, providing information on the demographics, personal medical history, 
indication of any previous OGD undergone, duration of symptoms, family history of 
GC or other cancers, previous history of peptic ulcer disease, any usage of antibiotics 
and acid suppressive therapy, smoking, alcohol consumption and any concomitant 
medical illness. The questionnaires were updated annually during yearly follow up. 
OGD and Biopsy 
Patients who had an endoscopy performed not more than 12 months prior to time 
of recruitment were enrolled in the study. The OGD reading was taken as baseline. 
Patients who had never had endoscopy or had an endoscopy performed more than 
12 months prior to time of recruitment would undergo a prospective baseline 
endoscopy. A video-recording of the endoscopy was carried out during the 
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procedure for agreement, validation and comparison purposes.  Subsequently, gastric 
mucosal biopsies were taken. The gastric mucosal biopsies were taken based on the 
Updated Sydney System as described in the next paragraph. In addition, cardia 
biopsies were taken (Figure 2.2). The locations are defined as follows: 
 A1- lesser curvature of the antrum, within 2-3cm of the pylorus. 
 A2- greater curvature of the antrum, within 2-3cm of the pylorus. 
 IA- incisura angularis. 
 B1- lesser curvature of the corpus, 4cm proximal to the angulus. 
 B2- middle portion of the greater curvature of the corpus, 8cm from the 
cardia. 
 Cardia (C) - within 1 cm below the OGJ (defined as the point where gastric 
folds disappear). 
All biopsy samples were assessed for degree of chronic gastritis, HP infection, 
atrophic gastritis and intestinal metaplasia by two independent experienced 
pathologists. These were scored using the updated Sydney system classification. 
Intestinal metaplasia were classified into mild, moderate and marked using a special 
staining technique (Alcian blue, PAS.)  
Blood collection 
40mls of fasting blood were drawn from each subject at the baseline visit and when 
subjects reached study primary endpoint. 20mls were collected in plain tube (BD 
Vacutainer® Plus plastic serum tube) for serum and another 20mls were collected 
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with CPT tube (BD Vacutainer® CPT™ with Sodium Citrate) for plasma and 
mononuclear cell. During Feb 2006 and Apr 2009, EDTA tube (BD Vacutainer® 
CPT™ with Polymer gel and K2EDTA) was used to obtain plasma before transfer to 
CPT tube for mononuclear cell. In the event that the primary endpoint was not 
attained, an additional 20mls of blood was drawn at the last visit of this surveillance 
programme. 10mls was in plain tube while another 10mls was in CPT tube. The 
serum/plasma and white blood cells were stored in -80 degree freezer or liquid 
nitrogen tank. The baseline serum was assayed for HP antibodies and serum 
pepsinogen routinely.  
Follow up 
Subjects were requested to undergo surveillance endoscopy at Year 1, 3 and 5. 
Biopsies were collected during these visits. If the subject, for clinical or medical 
reasons, required an endoscopy within 3 months prior to the scheduled surveillance 
endoscopy, then additional biopsies were carried out during the procedure. This was 
taken as the surveillance endoscopy reading.  
All subjects were followed-up annually at the clinic or via telephone for symptom 
review when they were not due for endoscopy surveillance that year. Clinical data 
was collected and the database was updated. 
Histology Analysis 
All biopsy samples were assessed for degree of chronic gastritis, HP infection, atrophic 
gastritis and intestinal metaplasia by two independent experienced pathologists. These 
were scored using the updated Sydney system classification. Intestinal metaplasia was 
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classified into mild, moderate and marked using a special staining technique (Alcian 
blue, PAS.)  
Endpoints  
Subjects who developed high grade dysplasia, intramucosal carcinoma and 
adenocarcinoma were considered to reach endpoints.  
Data Monitoring  
The GCEP study used a web-based system for data collection. Data were entered 
directly from source document to the electronic case report form. All study 
coordinators and investigators were given unique identification and password to access 
the database. The source document was monitored by independent reviewers before 
entry into database.  
Sample Size Calculation 
Based on Singapore cancer registry data, the incidence rate for GC in Chinese males 
aged 50-70 is 25.9 per 100,000(117). The incidence rate of GC in high risk groups such 
as patients with premalignant lesions, was reported as 0.1-1.1% which included all age 
groups (118, 119). In this study, the outcome is number of subjects who develop GC, 
including adenocarcinoma, intramucosal carcinoma and high grade dysplasia. As 
GCEP is a 'high-risk' group comprising high-risk subjects of Chinese ethnicity, patients 
who were over 50 years, with HP infection, or known pre-malignant histology such as 
atrophic gastritis and intestinal metaplasia, we estimated an incidence rate of 0.5% 
based on the Singapore cancer registry data and literature search.    
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50 cases of GC or high grade dysplasia are required to detect putative risk factors with 
odds ratio (OR) >2.5 at power of 80% and p-value <0.05. Based on an estimated 
incidence rate of 0.5%, a cohort size of 3000 subjects under surveillance for at least 5-
years was considered appropriate.  
2.2 Singapore Chinese Health Study  
The Singapore Chinese Health Study (SCHS) is a prospective cohort for long-term 
study of dietary, genetic and environmental determinants of cancer and other chronic 
diseases (120). Altogether, 63,257 Chinese men (n=27,959) and women (n=35,298), 
aged 45-74 years were recruited between April 1993 and December 1998 from 
permanent residents or citizens of Singapore residing in government-built housing 
estates (about 80% of Singaporeans reside in such estates). Recruitment was restricted 
to two major dialect groups of Chinese in Singapore: the Hokkiens and Cantonese. 
The details of the study design had been described. Written informed consent was 
obtained from all subjects enrolled in the SCHS. The study was approved by the 
Institutional Review Boards of the National University of Singapore.  
Baseline interview 
At recruitment, the subjects were interviewed in person at home by a trained 
interviewer using a structured questionnaire, which covered demographics, use of 
tobacco, current physical activity, menstrual/reproductive history (women only), 
occupational exposure, medical history and family history of cancer. Information on 
current diet, including alcohol consumption, was assessed using a 165-item food 
frequency questionnaire that has been validated against a series of 24-h dietary recall 
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interviews (120). The Singapore Food Composition Table was used to estimate 
average daily intake of 96 nutrient and non-nutrient compounds for each study subject.  
Blood collection 
Between April 1994 and December 1999, blood and single-void urine specimens were 
collected from a random 3% sample of study participants. Details of the biospecimen 
collection, processing and storage procedures have been described previously (121). 
Between January 2000 and April 2005, specimen collection was extended to all 
surviving cohort members and specimens from 32,543 subjects were collected, 
representing a consent rate of about 60% of surviving cohort participants at that time. 
Incident GC cases occurring within the SCHS cohort were identified through the 
population-based cancer registry in Singapore. The nationwide cancer registry has been 
in place since 1968 and has been shown to be comprehensive in its recording of cancer 
cases. As of 12 Dec 2010, there were a total of 650 subjects diagnosed with GC. 
Amongst them, 222 GC subjects donated blood samples. 178 cases donated blood 





Figure 2.1 Recruitment of subjects in GCEP study 
No. of subjects referred 
4085 
No. of subjects enrolled 
3094 
No. of refusals 
991 
No. of subjects having 
baseline OGD with biopsy 
2975 
Withdrawals because of 
no BL OGD or no 









   A1- lesser curvature of the antrum, within 2-3cm of the pylorus. 
 A2- greater curvature of the antrum, within 2-3cm of the pylorus. 
 IA- incisura angularis. 
 B1- lesser curvature of the corpus, 4cm proximal to the angulus. 
 B2- middle portion of the greater curvature of the corpus, 8cm from the 
cardia. 
 Cardia (C) - within 1 cm below the OGJ (defined as the point where 
gastric folds disappear). 
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C h a p t e r  I I I  
FEASIBILITY OF ENDOSCOPY SURVEILLANCE AND RISK FACTORS 
OF EARLY GASTRIC NEOPLASIA IN A HIGH RISK COHORT 
3.1 Introduction  
Screening for GC is not commonly practiced in other countries because of the 
comparatively lower incidences of GC(122). More targeted screening in the high-risk 
subpopulation to detect early GC in countries where the incidence of GC is 
intermediate is a possible option (117, 123). In Singapore, the age-standardized rate of 
GC incidence rate was 10.9 per 100 000 in 2008 (4), which was in the intermediate 
level. The proven risk factors such as gender, age(2, 124),  HP infection(13, 125), 
smoking, alcohol(34, 37, 126), dietary factors(127, 128), family history(43, 129, 130) 
and premalignant lesions such as intestinal metaplasia, atrophy gastritis could help 
select the subjects at high risk of GC. Various genetic factors and recently discovered 
molecular markers had also been reported to be associated with increased risk of GC.  
To define criteria of risk stratification in the intermediate population for targeted 
screening, and to develop the guidelines on the frequency of surveillance endoscopy, a 
large scale study in a multicentre setting is required.  
The primary objective of the Gastric Cancer Epidemiology and Molecular Genetics 
Program (GCEP) is to identify predictive risk factors from a high risk cohort and to 
develop an optimum approach and cost-effective algorithm for targeted screening for 
GC in the Singapore Chinese population.  
In this chapter, there are two studies based on the data from GCEP cohort. In the first 
study, we described the baseline demographics of the population, the prevalence of 
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gastric premalignant lesions in Singapore Chinese population who are at the high risk 
of GC. We also discussed the clinical characteristics and stage of 18 early GC or high 
grade dysplasia cases (early gastric neoplasia, EGN) diagnosed in the cohort. In the 
second study, we evaluated the association between clinical risk factors as well as the 
premalignant lesions and the early gastric neoplasia (EGN). 
3.2 Method 
A total of 2975 subjects who had had both baseline endoscopy and histology 
examination results were included in the analysis. Descriptive statistics were produced 
for demographic and baseline characteristics. In addition, the percentage of early 
gastric neoplasia detected in the GCEP programme was compared with the one in a 
hospital-based GC registry.  
Identification of EGN cases 
EGN cases include gastric adenocarcinoma, intramucosal carcinoma (IMC) or high 
grade dysplasia (HGD). 18 EGN cases were identified during the baseline OGD or 
surveillance OGD and confirmed by the histology examination.  
Statistical Analysis 
Statistical analysis was performed with IBM SPSS Statistics (version 20), a 2-tailed P 
value of less than 0.05 was considered statistically significant. Descriptive statistics 
were produced for demographic and baseline characteristics. Means and SDs were 
generated for continuous variables. Frequencies and percentages were generated for 
categorical variables. The Pearson's chi-square test was used for categorical data to 
compare proportions of each candidate risk factor - age, gender, education level, 
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smoking, alcohol consumption, family history of GC, atrophic gastritis and intestinal 
metaplasia (IM). Multiple logistic regression models were used to analyze the risk 
factors for EGN.   
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Study 1 – Systematic Endoscopic Surveillance in a High-Risk Cohort is 
Feasible for the Detection of Early Gastric Neoplasia (EGN) 
3.3 Result 
A total of 2975 subjects with a mean age of 59±7 years (range 50-86 years), with 
baseline endoscopy and histology examination were included in the current analysis. 
52% were males, 22% had current or previous history of smoking, 17% had alcohol 
consumption, 16% had family history of GC, and 39% had history of HP infection 
(Table 3.1).  
Of the 2975 subjects, 14% had no risk factor, 23% had one risk factor, 30% had two 
risk factors and 33% had three or more risk factors (Table 3.2). 
All subjects in GCEP must have one baseline endoscopy which could be either a 
clinical endoscopy performed no more than 12 months prior to recruitment or a 
prospective endoscopy performed under GCEP protocol. With the 2975 subjects, 
88% had chronic gastritis, 21% presented with current HP infection, 18% had atrophic 
gastritis, 47% had intestinal metaplasia, 6% had fundic or neoplastic polyp and 6 
subjects (0.2%) had low or moderate grade dysplasia during the baseline OGD (Table 
3.3).  
A total of 18 EGN were detected through surveillance endoscopy with an average 
follow up of 3 years; 12 of them were stage 0 with either high grade dysplasia (HGD) 
or intramucosal carcinoma (IMC). Six  invasive cancers were detected in stages 1A and 
1B (Table 3.4); 17 out of 18 had intestinal metaplasia, 15 out of 18 had atrophic 
gastritis and 16 out of 18 had had HP infection history. Eleven of them were male and 
the mean age was 65 years (Table 3.5). All subjects survived after treatment. Among 6 
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cases of invasive cancers (stage 1A and 1B), 4 were removed by subtotal or total 
gastrectomy and the other 2 were cured by endoscopic submucosa dissection (ESD). 
Out of 12 HGD or IMC, 2 underwent subtotal gastrectomy, 5 were cured by 
endoscopic mucosa resection (EMR) or ESD. The rest 5 cases of high grade dysplasia 
did not undergo any treatment because the lesion was not detected again in the repeat 
endoscopy.  
Three gastric neoplasia cases were found in baseline endoscopy. The other 15 cases 
were detected during surveillance endoscopies with the average surveillance period of 
28 months or median surveillance period of 23 months, ranging from 6 to 74 months 
(Figure 3.1). Out of 15 GC, 3 cases (no. 6, 10 and 18 in Table 3.6) had had the 
surveillance endoscopy 6 months or less prior to the detection of gastric neoplasia. 
This may indicate that the cancers were missed at the previous endoscopy or the lesion 
had developed within the 6 months interval period. Among the 12 other cases, the 
intervals between last endoscopy prior EGN and the endoscopy with EGN diagnosis 
were between 11 – 29 months. In our study, the interval between the most recent 
normal endoscopy and the diagnosis of cancer endoscopy did not affect the stages of 
cancer.  The long term survival will be monitored and compared in the future. Out of 
18 EGN, 9 cancers were detected at antrum, 5 from body and 4 from incisura. Four 
out of 18 neoplasia cases presented as polyps and another 3 as ulcers (Table 3.6). 
The stage distribution in the 18 EGN detected in GCEP was compared with the 
hospital based GC registry (GASCADII study) (Table 3.7). GASCADII study 
recruited all newly diagnosed GC cases from National University Hospital and Tan 
Tock Seng Hospital. The study started in 2006. Based on histology examination, 310 
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Chinese were diagnosed with GC between 2006-2011; 135 patients(44%) were 
diagnosed in early stage (stage 0, 1A, 1B and 2) while 175 (56%) were in late stage 
(stage 3A, 3B and 4). In 175 late stage subjects, 111 were in stage 4. In GCEP study, all 
18 cases (100%) were in early stage (stage 0, 1A or 1B), which was significantly more 
than the 44% diagnosed in early stage in GASCADII (p<0.001).  
3.4 Discussion 
With 18 EGN diagnosed in the programme, our study demonstrates that GC 
screening in selected subjects is feasible. Over 3000 Chinese subjects above 50 years 
old were recruited for our study. This population could be further refined to limit the 
screening programme to those with additional risk factors which could be determined 
with data from our cohort after more patient-years and more cancers are diagnosed 
with additional follow-up. Personal medical history and family history of GC were 
collected prospectively, and endoscopic surveillance with follow-up over a minimum 
of 5 years was offered. In addition to investigating the risk factors associated with GC 
and design of a cost-effective screening programme, many other questions could 
potentially be addressed, including the subtype of intestinal metaplasia, progression or 
regression of lesions, implication of HP eradication and cost-effectiveness of 
endoscopy screening in Singapore. In addition, interesting findings could be made 
through the natural follow up of this group of subjects. This includes the genomic 
characteristic of those early GC cases, predictive factors of recurrence and the steps of 
the progression of premalignant lesions to GC. The discovery or validation of 
genomics or proteomics biomarker is also feasible because tissue and blood have been 
collected prospectively.  
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The choice of the study population was based on scientific, practical and ethical 
considerations. In Singapore, the incidence of GC was only 13.9 per 100,000 people 
per year in males and 8.3 per 100,000 people per year in females in 2008 (4). As GC 
incidence was higher in Chinese than in Malays or Indians and cancer increases sharply 
in older people, the GCEP study targeted Chinese over 50 years old who were at high 
risk of GC. With the sample size of 3000, we could produce definitive relative risk for 
some risk factors. It was not feasible to recruit from the asymptomatic general 
population because endoscopy is invasive and the compliance of endoscopy screening 
may be poor in the general population who has no abdominal symptom. The overall 
participation rate in a national GC screening programme which offered either 
photofluorography or endoscopy in Korea was only 20.5% (116) and 
photofluorography was preferred among the participants. In our study, the compliance 
rate of endoscopy is about 81% which is the highest among all endoscopy screening or 
surveillance programmes (116, 118).   
Although the highly selected study population was logistically advantageous and 
scientifically well founded, there are limits to the generalizability of the findings as we 
only investigated Chinese who were over 50 years and most of them were recruited at 
Gastroenterology clinics. Risk factors such as HP infection were removed when 
detected during the surveillance endoscopy. Dietary factors were not measured in 
detail because of the complexity of life-time dietary habits over time. As diet may 
interact with HP infection and genetic factors, we may not be able to report a justified 
effect of genetic susceptibility. Most of our predictive factors were associated with 
intestinal type GC. Little has been reported for diffuse type. The progression of diffuse 
type carcinoma will be difficult to assess. Due to the small number of cancer cases, we 
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may not be able to determine the risk factors associated with intestinal and diffuse type 
of GC by stratification analysis. The same applies for gastric cardia cancer which has a 
different etiology from the distal cancers.  
The benefit of this surveillance programme to this group of high risk subjects is early 
detection of GC and the prevention of GC by the eradication of HP infection and the 
removal of premalignant lesion such as low/high grade dysplasia.  
In patients diagnosed with EGN in our study, the interval between the last two 
endoscopies ranged from 2-29 months. In 3 cases, the interval was ≤ 6 months. One 
of them had history of moderate grade dysplasia and was under endoscopy surveillance 
every 2 months. Another two patients presented with symptoms and clinical OGDs 
were provided. A tubulovillous polyp was found in one of them and the histology of 
dissected tissue showed focal high grade dysplasia. Out of 12 HGD/IMC detected, 
lesions in 5 subjects (42%) were not detected in the subsequent repeat endoscopy. 
There are two possible reasons. First, the focal high grade dysplasia was so small that it 
had been removed during biopsy. Secondly, the lesion could be missed due to 
sampling error.  
As endoscopic surveillance is costly, there were not many similar studies. Most of the 
past studies had small sample sizes, were retrospective or without standard protocol 
for biopsy taking. J L Whiting et al.(118) reported 14 cancers (8.4%) which were 
detected after 10 years follow up in a group of 166 subjects. In the study, 67% of 
cancer cases were detected in stage I or II. The interval between the most recent 
benign endoscopy and the endoscopy diagnostic of malignancy ranged from 1-50 
months. The prolonged interval was the greatest factor in the diagnosis of later stage 
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disease. This was also due to the poor compliance rate of annual endoscopy of 50%. 
Because of the high compliance rate in our study, we were able to detect early GC in 
stage I or high grade dysplasia, intramucosal carcinoma.  
Chung SJ et al. observed 58,849 patients who underwent endoscopy during health 
checkup at Seoul National University Hospital Healthcare System Gangnam Center in 
Korea (131). The patients were stratified into repeat OGD and infrequent OGD 
groups. Repeat OGD group was further split into annual endoscopic or biennial 
screening groups. The result showed annual surveillance improved the early detection 
of GC but there was no significant difference on 5-year survival rate between the 
groups. This is in agreement with what we have observed in our GCEP study. This 
Korea study had the biggest sample size among all endoscopic studies but the biopsy 
taking in the study was determined by individual endoscopist without following any 
standard protocol. In our study, we follow Updated Sydney recommendation and 
classification for the biopsy collection and reading. Our histology result is based on the 
consensus of two independent experienced pathologists.  
Another study(132) conducted in Spain around 12 years ago included 478 subjects who 
had gastric biopsy with the diagnosis of normal mucosa, non-atrophic gastritis, 
atrophic gastritis, complete or incomplete intestinal metaplasia. A new biopsy was 
taken when the subject agreed to join the study. Twenty-three GC cases were detected 
(4.8%) with yearly incidence of 0.377%. Incomplete intestinal metaplasia and family 
history of GC were significantly associated with risk of GC with HR (95% CI) of 11.3 
(3.8-33.9) and 6.1 (1.7-22.4) respectively. The study proved that the subtype of 
intestinal metaplasia was useful for the prediction of GC risk. However, the subjects in 
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this study were recruited retrospectively, so biopsies in the baseline endoscopy were 
not collected following a standard protocol. The number of biopsy was less in the 
baseline endoscopy. There was only one follow up endoscopy. This made the 
assessment of the progression of gastric premalignant lesions less reliable. Vries et 
al.(119) had conducted a retrospective review based on the Dutch nationwide 
histopathology registry (PALGA). The annual incidence of GC was 0.1% in atrophic 
gastritis, 0.25% in intestinal metaplasia, 0.6% in mild-moderate dysplasia and 6% in 
severe dysplasia within 5 years of follow-up. It showed that patients with premalignant 
gastric lesions are at higher risk of GC compared to those without any lesion. 
In Japan, 5-year survival rate of all GC patients has remained at around 68% (5, 133). 
In Korea, the survival rate had increased dramatically from 42.8% during the period 
1993-1995 to  63.1% during the period 2004-2008 (134). This could be explained by 
the early detection and the improvement of GC treatment. Based on a large scale 
population cohort study in Japan, the early stage GC was 59% of total number of GC 
detected in screened population, compared to 45% in unscreened population (113). 
The annual endoscopic screening observational study in Korea had reported better 
results – incidence of early GC was 98.6% in the group with annual endoscopy and 
56.7% in the group with infrequent screening.(131) In our GCEP surveillance 
programme, the preliminary data showed that 100% of GC case detected was in early 
stage. We compared with the hospital GC registry data (GASCADII study) which 
indicated only 44% of GC detected in hospitals were in early stage (p < 0.001). 
Subjects in GASCADII and GCEP studies were all from public hospitals. Without 
GCEP study, most of the GC cases would be detected in late stage which has poorer 
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survival rate. This suggested that endoscopy surveillance is required in order to detect 
cancer in early stage.   
As a prospective cohort study, the design of GCEP reduces the potential bias 
problems. By targeting on hospital subjects, we have had high compliance rate of 
endoscopy surveillance which helps detect GC in early stage. However, the study 
population does not reflect the general Chinese population and it represents a Chinese 
population who are at high risk of developing GC. The generalizability of the findings 
will limit to Chinese who were over 50 years with gastro symptoms.  
The sample size may be underestimation as the incidence rate of GC continues falling. 
Besides, the subjects were mainly from the hospitals. It is possible that the subjects in 
our study had easy access to the hospital facility and were more willing to visit the 
hospital when they felt uncomfortable. This may suggest that this special group of 
people had better socioeconomic status and they may also have good awareness of 
cancer prevention through their contact with doctors. The incidence of GC in this 
high risk group may not be as high as we estimated. 
In summary, GC surveillance is feasible in a select group of high risk subjects. The 
number of EGN detected in surveillance group is significantly higher than in the usual 
specialist clinic. With the multi-centre setting, cohort design and uniform prospective 
pathologic examination, further follow-up of our cohort will contribute data for the 
determination of risk factors associated with GC and aid in the understanding of the 
progression from premalignant lesions to GC. The findings will help provide 
recommendations for future screening guidelines of GC and the surveillance guidelines 
for gastric premalignant lesions.  
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Table 3.1 Baseline Characteristics of GCEP population 
 
Total No. subjects  2975  100% 
Mean Age ± SD 59±7  
Age                 50-59 
                        60-69  








                       Male    








                       Tertiary  
    Junior college 
                       Secondary 











Smoking (%)  
                      Never 
                      Past 









Alcohol consumption   520  17%  
Family history of GC                     468 16% 
HP infection History (%) #       1160  39%  
Peptic ulcer (current or previous) 
                       Absent 
                       Gastric 
                       Duodenal 











Diabetes 420 14% 
Hypertension 1193 40% 
Personal history of cancer other than GC 154 5% 
Family history of other cancers 1146 39% 
Statin 714 24% 
# HP is considered as present if any one of the following is positive: HP infection 




Table 3.2 Risk factors in GCEP subjects 
Risk factors include family history of GC, smoking, H.pylori infection 
(history, histology, serology), atrophy, IM 
 
 
No. of Risk Factors No. of subjects (%) 
0 429 (14%) 
1 696 (23%) 
2 882 (30%)  
≥3 968 (33%) 









Chronic Gastritis  
 
2611 (88%) 









Fundic or neoplastic Polyp 188 (6%) 








Table 3.4 Stage of early gastric neoplasia detected  
 
Stage N = 18 Treatment 
0 (High grade dysplasia) 5 No treatment 
0 (High grade dysplasia) 6 EMR, ESD, Gastrectomy 
0 (Intramucosal carcinoma) 1 Gastrectomy 
1A 5 Gastrectomy, ESD  
























# HP is considered as present if any one of the following is positive: HP 
infection history by reviewing the case notes, HP current infection based on 
histological examination, HP serology test 
  
Risk factors N=18  
Intestinal metaplasia 17 94%
History of H.pylori infection# 16 89%
Atrophic gastritis 15 83%
Male 11 61% 
Smoking   9 50%
Family history 3 17%
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1 F 76 0 Antrum Sep 2004 Sep 2005 Aug 2006 23 11 ESD 
2 F 50 0 Incisura Mar 2006 =D1 Mar 2007 12 12 No Rx 
3 M 58 0 Incisura Jan 2007 =D1 Jan 2007 0 0 Subtotal 
Gastrectomy 
4 M 50 0 Antrum June 2007 =D1 June 2008 13 13 ESD 
5 F 55 1A Antrum Apr 2006 Apr 2007 Apr 2008 24 13 Subtotal 
Gastrectomy 
6 F 77 0 Antrum Jan 2007 Jan 2008 June 2008 17 5 ESD 
7 M 75 0 Antrum Aug 2004 Aug 2004 Aug 2004 0 0 EMR 
8 M 54 1B Body Nov 2006 Nov 2007 Mar 2009 28 16 Total 
Gastrectomy 
9 F 68 0 Incisura Sep 2006 =D1 Apr 2008 19 19 No Rx 
10 M 60 0 Antrum Aug 2008 =D1 Feb 2009 6 6 No Rx 
11 M 69 0 Body Apr 2007 May 2009 June 2010 39 13 EMR 
12 M 78 0 Antrum Sep 2007 Sep 2008 Sep 2010 37 25 No Rx 
13 M 73 0 Antrum Dec 2010 Dec 2010 Dec 2010 0  0 Subtotal 
Gastrectomy 
14 M 58 1A Body Jan 2010 =D1 Jan 2011 12 12 Total 
Gastrectomy 
15 M 69 1A Body Sep 2009 =D1 Jan 2011 16 16 Total 
Gastrectomy 
16 M 62 0 Incisura Jan 2008 Jan 2009 June 2011 41 29 No Rx 
17 F 67 1A Body June 2006 May 2011 July 2012 74 14 ESD 
18 F 72 1A Antrum Aug 2007 Aug 2012 Oct 2012 63 2 ESD 
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Table 3.7 Difference of stages of GC between hospital cancer registry 









No. of subject      
(N = 310) 
No. of subject     
(N = 18) 
Early GC 135 (44%) 18 (100%) p < 0.001 
0 5 (1%) 12 (73%)
1a 47 (15%) 5 (20%)
1b 44 (14%) 1 (7%)
2 39 (13%) 0
Late GC 175 (56%) 0
3a 40 (13%) 0
3b 24 (8%) 0




Figure 3.1 The interval between the diagnosis of EGN and the most 





Horizontal bars denote surveillance duration in months between 
baseline endoscopy to the development of EGN. The dot on the bar 
indicates the most recent endoscopy prior to detection of EGN and the 
number in brackets indicates the time in months from the latter to 
diagnosis.     
 
^ case number 7 had one clinical endoscopy 4 months before enrolled in the 
study 
^^ case number 13 had one clinical endoscopy 13 months before enrolled in 
the study 
*case number 18 was diagnosed with moderate dysplasia two months before 










































Study 2 – Clinical Risk Factors and Premalignant Lesions of Gastric Cancer 
in High Risk Cohort  
3.5 Result 
Univariate and multivariate analysis were performed for risk factors such as age, 
gender, education level, smoking, alcohol consumption, family history of GC, HP 
infection history as well as premalignant lesions – atrophic gastritis and IM (Table 3.8 
and 3.9).  Age above 70, primary education level or below, smoking, atrophic gastritis 
and IM were statistically significantly associated with early gastric neoplasia in both 
univariate and multivariate analysis with adjusted ORs (95% CI) of 3.24 (1.17-8.98), 
2.72 (1.01-7.30), 2.89 (1.13-7.44), 3.71 (1.42-9.72) and 8.01 (1.05-60.86) respectively. 
HP was statistically significantly associated with early gastric neoplasia in univariate 
analysis with OR of 4.92 (1.13-21.44) but the effect was not significant after adjusted 
for other risk factors. Gender, alcohol consumption and family history of GC did not 
demonstrate difference between early gastric neoplasia group and control group.  
The relationship between two premalignant lesions (atrophic gastritis and IM) and age, 
gender, education level, smoking, alcohol consumption, family history of GC and HP 
infection history were assessed. Subjects over 70 years old were more likely to have 
atrophic gastritis or IM. The proportion of past history of HP infection increased in 
the groups of normal or chronic gastritis, atrophic gastritis without IM and IM. The 
prevalence of HP infection in IM group was as high as 74%. Greater proportions of 
primary education or below and alcohol consumption were seen in IM group 
compared with the other two groups with less severe lesions. The overall prevalence of 
male gender, smoking and family history of GC were 52%, 22% and 16% respectively, 
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and there were no significant difference were observed among various groups. (Table 
3.10) 
3.6 Discussion 
We performed interim analysis for the GCEP study, a large GC cohort with over 3000 
subjects enrolled. Endoscopy surveillance was provided at 1-3 years interval. We found 
that age over 70 years old, primary education or below, smoking, atrophic gastritis and 
IM were strongly associated with early gastric neoplasia.  
Eighteen cases of early gastric neoplasia were identified after an average of 3 years of 
follow up and the incidence rate was estimated to be about 0.2% per year. This is 
similar to a prospective study in China with incidence rate of 0.22% (135) and slightly 
lower than the result from a large prospective study in Japan in which 36 GC was 
detected in 1245 HP positive subjects and the incidence rate was estimated to be 
0.37% (13), a Caucasian study in Spain (132). Those studies all targeted on high risk 
subjects but had long follow up (4.5 - 12 years).  
The result showed IM was a strong and significant risk factor in the GC risk prediction 
in our high risk cohort. 17 out of 18 (94%) of early gastric neoplasia cases had IM. The 
only one case which was IM negative was diffuse type of GC. It showed IM is a 
necessary step in the development of high grade dysplasia or intestinal type GC. The 
proportion of IM cases in our cohort is 61% and the result was based on the all 
surveillance endoscopy examinations following with histology confirmation and the 
no. of endoscopy examinations varied from 1 - 5.  If any one of the histology reports 
indicated subjects had IM, we will classify this subject as IM although sometime IM 
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may be absent in subsequent endoscopy or prior baseline endoscopy due to sampling 
error. There has been some debate on whether IM was reversible (112, 136-138) and it 
seemed IM was less likely to regress. Studies on IM progression or regression had 
small sample size or short follow up period and sampling error was the big problem in 
assessing the IM regression. The indirect evidence was from a randomized trial on the 
effect of HP eradication on GC prevention (29). HP eradication reduced GC incidence 
rate only in the subgroup without any premalignant lesions but there was no difference 
between placebo and eradication groups after 7.5 years follow up. It suggested the 
lesions were unlikely to return to the less severe lesions or normal status. Nevertheless, 
our estimation of the power of IM in predicting GC risk was similar to other studies 
(118, 119) and IM was proved to be an important risk factor in selecting high risk 
people. Some studies had also showed incomplete type of IM characterized by brush 
border cells and goblet cells was at elevated risk of developing GC compared with 
complete IM represented by hybrid intermediate non-goblet mucous columnar cells 
with cytoplasmic drops of different size (132).  
The prevalence of atrophic gastritis was 27% in this cohort but it always co-existed 
with IM. Only 98 subjects had atrophic gastritis without IM. Atrophic gastritis was 
characterized by the loss of gastric glandular cells due to long term chronic 
inflammation. It is believed atrophic gastritis will eventually lead to IM, dysplasia and 
GC (64). Subjects with atrophic gastritis were reported to have 3.5 – 25-fold increased 
risk of GC and the risk was higher for intestinal type of GC than in diffuse type GC 
(139-141). In our cohort, two out of 18 GC were diffuse type and the adjusted OR for 
the risk of atrophic gastritis was 3.71. Blood pepsinogen level was used as marker for 
atrophic gastritis as it was believed to reflect the functional status of gastric mucosa 
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(142). Loss of gastric glandular cells resulted in low pepsinogen level (143, 144). 
Pepsinogen (PG) had been widely used as screening tool in Japan because it was less 
invasive and cheaper (145-147). In Chapter 5, we will discuss the usefulness of the HP-
PG panel in GC risk prediction in Singapore Chinese population.  
Sufficient evidence from cohort studies as well as case-control studies proved the 
causal relationship between HP infection and GC (12, 13, 148). The risk of HP 
reported from different studies varied greatly and the range of ORs were 2 – 8 (6-9, 
65).  The difference in the risk of HP infection could possibly be due to the various 
methods used to detect HP infection. In our study, we collected results from HP 
serology test, histology examination and also from reviewing case notes. If any one of 
the tests were positive for HP, we considered the subject had had HP infection 
currently or in the past.  In the study with stratification analysis, HP infection was 
found to have much higher risk in noncardia GC with OR of 20 (149). Our study 
showed HP infection was associated with increased risk of GC in univariate analysis 
but failed to show statistically significant effect in multivariate analysis.  This may be a 
common scenario in the high risk population and the premalignant lesion study in 
Spain which had the high prevalence of HP could not show significant effect of HP 
too (132).  
Other than premalignant lesions, we found three more clinical risk factors – old age, 
low education level and smoking were statistically significantly associated with the 
development of GC. They were all well-known risk factors for GC. Education level 
represented socioeconomic status. A nested case-control study in a prospective cohort, 
the European Prospective Investigation into Cancer and Nutrition (EPIC), low 
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education level was found to be associated with GC with HR 1.56 (95% CI, 1.02-
2.33) (150). An extreme high HR was observed when limit to intestinal type GC with 
HR of 7.69 (95% CI, 2.27-25). In the same EPIC cohort, ever smoker was found to 
have 1.45 (95% CI, 1.08–1.94) (151).  
In this study we examined the possible risk factors associated with risk of IM. The 
results showed subjects who were age over 70, primary education or below and had 
history of HP infection were more likely to develop IM. It seemed the development of 
IM and GC had some common risk factors. In countries where GC incidence is too 
low, the risk factors of IM could be used to identify those at high risk of GC.  
Our study here has confirmed that the premalignant lesions atrophic gastritis and IM 
were associated with increased risk of GC with adjusted OR of 3.71 and 8.01 
respectively in a high risk Chinese cohort. The other clinical risk factors such as age 
over 70 years old, smoking, low education level were also validated in our cohort with 
significant ORs. A few strengths of using our cohort to estimate the predictive power 
of those known risk factors: prospective study reduces the chance of selection bias and 
recall bias. The variables were documented before the subjects reached endpoint. The 
majority of risk factors collected by interview were able to be verified by reviewing 
case notes because our subjects were recruited from the hospitals. The premalignant 
lesions were confirmed based on multiple surveillance endoscopies and this had 
reduced the chance of underestimation due to sampling error. There were some 
limitations here. Our study is not ready for stratification analysis to evaluate the 
difference of the effect of risk factor between intestinal type of GC and diffuse type of 
GC. The cardia GC and non-cardia GC were also considered to have different 
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pathway in GC development. We hope this limitation can be overcome after we 
complete five year surveillance for all 3000 subjects and accumulate more early gastric 
neoplasia cases. As our cohort is a high risk cohort, the prevalence of HP infection was 
high and the effect of this risk factor was clearly demonstrated.  
In summary, atrophic gastritis, IM, age over 70 years old, smoking, low education level 
will help us stratify the subjects into low, moderate and high risk groups. In addition, 
More attention should be paid to IM subjects due to its significantly higher OR 
compared with other risk factors. More studies are required to understand the 
progression from IM to GC and identify those IM cases which should be under 
frequent surveillance in order to detect the GC at early stage.  
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Table 3.8 Characteristics of GCEP cohort 
 GC Case   
(n=18) 
GC free in the 
cohort 
(n=2957) 
P value  
Age at enrolment  64.2 (9.2) 59.5 (6.9) 0.004 
Male (%) 11 (61) 1529 (52) 0.48 
Education (%)    
Primary and below 11 (61) 803 (27) 0.003 
Secondary and above 7 (39) 2154 (73)  
Smoking     
Never 9 (50) 2304 (78) 0.009 
Former/Current 9 (50) 653 (22)  
Alcohol drinking    
No 13 (72) 2442 (83) 0.225 
Previous/Current 5 (28) 515 (17)  
Family history of GC 3 (17) 465 (16) 0.99 
History of HP infection# 16 (89) 1826 (62) 0.025 
Chronic Gastritis 17 (94) 2594 (88) 0.72 
Atrophic Gastritis * 15 (83) 807 (27) 0.003 
Intestinal Metaplasia * 17 (94) 1817 (61) 0.003 
 
# HP is considered as present if any one of the following is positive: HP infection 
history by reviewing the case notes, HP current infection based on histological 
examination, HP serology test 





Table 3.9 Relative risk and adjusted relative risk for age, education, smoking, 





No. of GC cases 
(n=18) 
Odds  ratio  (95% 
CI) 
Adjusted  odds 
ratio (95% CI) 
Age (y)      
 50-69 6 1.00 1.00 
 ≥70 12 5.04 (1.88-13.53) 3.24 (1.17-8.98) 
Education   
Secondary and above 7 1.00 1.00
Primary and below 11 4.20 (1.62-10.87) 2.72 (1.01-7.30) 
Smoking   
No 9 1.00 1.00
Previous or current 9 3.53 (1.39-8.92) 2.89 (1.13-7.44) 
History of HP 
infection 
 
Absent 2 1.00 1.00
Present 16 4.92 (1.13-21.44) 4.05 (0.92-17.77) 
Atrophic gastritis  
Absent 7 1.00 1.00
Present 11 4.17 (1.61-10.78) 3.71 (1.42-9.72) 
Intestinal Metaplasia   
Absent 1 1.00 1.00
Present 17 10.61 (1.41-79.82) 8.01 (1.05-60.86) 
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Table 3.10 Characteristics of atrophic gastritis and IM 
 Normal or chronic 
gastritis without IM 




without IM * 
(n=98) P value 
IM* 
(n=1834) P value 
Total  
(n=2975) 
Age at enrolment  57.8 (6.1) 59.4 (7.1) 0.01 60.5 (7.1) <0.001 59.5 (6.9) 
Male  52% 49% 0.57 52% 1.00 52% 
Primary education 
or below 21% 21% 1.00 32% <0.001 27% 
Ever Smoker †  21% 15% 0.16 23% 0.22 22% 
Alcohol drinking 16% 11% 0.19 19% 0.04 17% 
Family history of 
GC 16% 17% 0.80 16% 1.00 16% 
History of HP 




† Ever Smoker refers to current smoker and ex-smoker 
# HP is considered as present if any one of the following is positive: HP infection history by reviewing the case notes, HP current 
infection based on histological examination, HP serology test 




C h a p t e r  I V  
STUDY 3 - GENETIC RISK FACTORS FOR GASTRIC CANCER AND 
PREMALIGNANT LESION OF GASTRIC CANCER  
4.1 Introduction  
GC is known to be a heterogeneous disease with multiple environmental factors 
and genetic factors implicated in the various gastric carcinogenesis pathways. There 
are a small number of GCs that are caused by hereditary diffuse GC syndrome 
mainly due to the mutation of E-cadherin (CDH1) gene on the chromosome 
16q22 (152). The syndrome has been well studied and gene mutation carriers who 
are also on HP eradication are recommended to undergo endoscopic surveillance 
at six monthly intervals or prophylactic gastrectomy after the age of 20.  
Two studies with new generation sequencing using GC samples had been 
published recently (153, 154). Wang et al. (153) from Pfizer had performed 
whole-exome sequencing on 22 GCs using the Illumina platform. The study 
identified the top 20 genes using driver-gene score including known driver gene 
of carcinogenesis such as TP53, PTEN and TTK. The study had also showed for 
the first time that ARID1A gene (a tumor suppressor gene) was the most 
frequently mutated gene in 83% of GCs with microsatellite instability (MSI), and 
73% of those with Epstein-Barr virus (EBV) infection. Zang et al. had reported 
consistent result on the ARID1A gene mutation and in addition, they found the 
mutation of a cadherin gene, FAT4 was also a key tumorigenic events (154).  
The etiologies and incidence of GC varies geographically. GC is common in the 
East Asia but is rare in North America and Europe. This can be partially explained 
by the difference in prevalence of HP (155). In Singapore, the Chinese has the 
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highest GC incidence rate while Indians and Malays have much lower incidence 
rate. HP infection may play an important role in race-associated GC risk. Ang TL 
from Changi General Hospital had evaluated the race difference in HP and GC in 
the Singapore population and found that HP prevalence was similar in Chinese and 
Indian (50%) but significantly lower in Malay (27%) (156).  It seems that some 
races are more susceptible to GC than the others, suggesting host genetic 
susceptibility plays an important role in GC development. Identification of those 
gene variants will help us better understand GC development and is also important 
in risk stratification and early detection. A few genome-wide association studies 
have been successful in exploring genetic susceptibility factors in Japanese, and 
Chinese (157, 158). The Japanese study published in 2008 found that the prostate 
stem cell antigen (PSCA) gene and Mucin 1 (MUC1) gene were significantly 
associated with diffuse type GC. This result has been validated in both Asian and 
Caucasian populations (159-162).  In genome-wide association study (GWAS) in 
Chinese population (158), gene PRKAA1 (encoding protein kinase, AMP-
activated, alpha 1 catalytic subunit) and ZBTB20 (encoding zinc finger and BTB 
domain containing protein 20) were identified as susceptibility genes in non-
cardia GC in addition to the two genes found in the Japanese study. Another 
Chinese study found a shared susceptibility locus in PLCE1 (encoding 
phospholipase Cε1) for GC and esophageal squamous cell carcinoma (163). The 
findings have been validated in other Chinese population and it had been shown 
that the PLCE1 gene variation was also associated with GC survival (164). 
HP has been classified as class I carcinogen due to its causative role in the GC 
development. Differing inflammatory responses between hosts may help to 
explain different outcomes for persons with HP infection. Therefore, the 
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association between GC susceptibility and inflammation-related gene 
polymorphisms had been evaluated in many studies. A meta-analysis showed 
IL1RN2 carriers had increased risk for both intestinal type and diffuse type GC 
in Caucasian population (165). In Asian populations, IL1B-31C carrier was found 
to be associated with reduced risk of GC. These polymorphisms could be used in 
conjunction with HP status and together with dietary and environmental factors 
to target screening programs towards individuals deemed to be at high risk. 
GC is thought to arise via a multi-step pathway that involves intestinal metaplasia 
(IM) as a precursor lesion (64). It has been estimated that 0.25-1.1% of IM 
lesions will progress to GC annually, representing an 18-78-fold increased 
lifetime risk of developing this disease in comparison to the general population 
(118, 119). In the present study, we have investigated a panel of 18 
polymorphisms in 14 candidate genes for their association with IM precursor 
lesions in a Singapore-Chinese population considered to be at increased risk of 
GC because of age greater than 50 years. These polymorphisms were chosen for 
study because previous research has shown them to be risk factors for GC. They 
included SNPs in genes involved in the immune response (IL-1β, IL-10, 
PTPN11) (166-168), folate metabolism (FR-α, MTHFR) (169, 170), cell growth 
(EGF, HER2) (171-173), cell survival (STCH) (174), cell invasion (MMP2) (175) 
and DNA damage or repair (NQO1, SULT1A1, TP53, ADPRT) (176-180).  
4.2 Methods 
Subjects 
Subjects were recruited from the Gastric Cancer Epidemiology and Molecular 
Genetics Program (GCEP) which was described in Chapter 2. Blood samples 
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from 374 individual subjects collected between April 2004 and December 2006 
were used for genotyping in the present study.  
IM was diagnosed from mucosal biopsies in three locations (antrum, body and 
cardia) for each subject and by consensus amongst three pathologists according 
to the updated Sydney System for the classification and grading of gastritis (181). 
In cases where HP was identified in biopsies, eradication therapy was 
administered according to standard clinical guidelines. For 339/374 (91%) 
individuals, the HP status was determined using the Helicoblot2.1 serology test 
(Genelabs Diagnostics, Singapore). In individuals where this test was not 
performed, the HP status was determined from histological examination of 
biopsies from the antrum, body and cardia, as well as from past medical history. 
Blood samples (8 mls) were collected into Vacutainer CPT tubes (Becton 
Dickinson, Franklin Lakes, NJ) and the mononuclear cells isolated and stored at -
80°C prior to DNA extraction using Tri-Reagent (MRC Inc, Cincinnati, OH). 
Helicoblot 2.1 serology test 
This serological assay uses a Western Blot nitrocellulose strip containing 
electrophoretically separated proteins from a bacterial lysate of an ulcer-causing 
type strain of HP and a recombinant antigen of HP (MP Biomedicals, Singapore). 
When incubated with diluted serum/plasma, specific antibodies against the 
various antigens, if present, will bind to the HP antigens on the strip. These 
bound antibodies appear as dark bands upon reaction with goat anti-human IgG 
conjugated with alkaline phosphatase and a 5-bromo-4-chloro-2-indolyl-
phosphate/nitroblue tetrazolium substrate solution. In order to identify the 
various bands present, the strip is compared with reference strips of non-reactive 
(negative) and reactive (positive) controls run concurrently. Determination of HP 
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seropositivity was based on criteria recommended by the kit manufacturer. They 
consist of (1), 116 kD (CagA) positive band present with one or more of the 
following bands: 89 kD (VacA), 37 kD, 35 kD, 30 kD (UreA) and 19.5 kD 
together, or with the current infection marker, (2) the presence of any one band 
at 89 kD (VacA), 37 kD or 35 kD, with or without current infection marker, or 
(3) the presence of both 30 kD and 19.5 kD with or without current infection 
marker. 
Selection of gene polymorphism panel 
A systematic literature search in PubMed was carried out using the terms "gastric 
cancer" and "polymorphism". From a total of 78 candidate polymorphisms 
identified, 18 were found to be significantly associated with the risk of GC and 
were therefore included in the current investigation of IM.  
Genotyping 
Table 4.1 shows the PCR primers, annealing temperatures and product sizes for 
17 SNPs investigated in this study by pyroseqeuncing. The 86-bp variable 
number of tandem repeats (VNTR) polymorphism in ILRN was genotyped using 
PCR followed by size analysis using gel electrophoresis. The primers and PCR 
conditions were the same as previously reported (182). Polymorphisms were 
recorded in their most commonly used notation for easy cross-referencing. For 
PCR, 50 ng DNA was amplified in a 25 μl reaction containing 1 × FastStart 
Reaction Buffer, 2 mM magnesium chloride, 10 μM deoxynucleotide mix, 500 
nM each of the forward and reverse primers and 1 unit FastStart Taq Polymerase 
(Roche Diagnostics, Mannheim, Germany). PCR cycling comprised of 4 minutes 
at 95°C, followed by 35 cycles of 30 seconds at 95°C, 30 seconds at the 
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appropriate annealing temperature and 30 seconds at 72°C, before conclusion 
with 7 minutes at 72°C. 
Pyrosequencing was performed by incubating the PCR products with 3 μl of 
streptavidin magnetic beads (Amersham Pharmacia Biotech, Uppsala, Sweden) 
and 1× binding buffer (10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, 0.1% Tween 
20) and mixing for 10 minutes at 37°C. The product mix was then denatured by 5 
seconds incubation in 0.2 M NaOH solution and washed in annealing buffer (20 
mM Tris-acetate, 2 mM magnesium acetate) for 10 seconds. The single-stranded 
products were transferred to an annealing buffer containing 15 pmol of the 
sequencing primer (Table 4.1) and incubated for 2 minutes at 80°C in a Hybaid 
Maxi 14 hybridization oven (Thermo Electron, USA). Pyrosequencing was then 
performed on a PSQ96MA pyrosequencer instrument (Biotage AB, Uppsala, 
Sweden). Samples that failed to give a genotype result after the first analysis were 
repeated up to two times. The genotyping success rate varied from 85-99% for 
the 18 polymorphisms. 
Statistics 
Univariate analyses were carried out by Pearson's chi-square or the Fisher's exact 
test to examine for associations between genotype distributions, IM status and 
clinical factors. As there were more than one polymorphism investigated in IL10 
and STCH, the haplotypes were also considered in the analyses. Variables found 
significantly associated with IM in the univariate analyses for all cases, and HP+ 
and HP- subgroups were entered in respective multivariate logistic regression 
models. The analyses were based on the assumption of a dominant genetic 
model. All statistical analyses were performed using SPSS 16.0 (SPSS Inc., 
Chicago, IL) software at the 5% significance level. The Woolf test was used to 
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test for homogeneity of OR between two strata. As each polymorphism was 
tested for association with IM independently, it was not necessary to control for 
the family-wise error rate. Thus, no adjustment was made for multiple testing. 
4.3 Results 
The characteristics of 374 subjects evaluated in this study are shown in Table 4.2. 
A total of 128 were diagnosed with IM and 246 without IM. No significant 
differences between IM+ and IM- groups were apparent for sex, family history of 
GC (including 1st degree and 2nd degree relatives), alcohol consumption (at least 
one unit of wine, beer or liquor per week) or smoking status (at least one 
cigarette per day for a minimum of one year). IM+ subjects showed a 
significantly higher incidence of HP infection and were also older (P < 0.05). 
Genotype frequencies for the 18 polymorphisms investigated for association with 
IM are presented in Table 4.3. All polymorphisms were in Hardy-Weinberg 
equilibrium (P > 0.05), with the exception of IL10 -819T/C, NQO1 609C/T and 
TP53 Arg72Pro. By univariate analysis, the NQO1 609 T allele was the only 
variant in the overall cohort that was significantly associated with IM (OR = 1.82, 
95%CI: 1.05-3.15, P = 0.032). In HP- individuals, only the PTPN11 rs2301756 A 
allele was significantly associated with IM (OR = 2.51, 95%CI: 1.16-5.40, P = 
0.019). Three polymorphisms in HP+ individuals were associated with IM in 
univariate analysis: the IL-10 819 C allele (OR = 2.32, 95%CI: 1.21-4.43, P = 
0.011), NQO1 609 T allele (OR = 2.61, 95%CI: 1.18-5.80, P = 0.018) and 
PTPN11 A allele (OR = 0.46, 95%CI: 0.21-0.99, P = 0.048). The haplotypes in 
IL10 and STCH were not significantly associated with IM in overall cohort, HP-, 
as well as HP+ groups. 
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In multivariate analysis that included all cases, HP status and age were 
significantly associated with IM, while the NQO1 T allele showing borderline 
association (Table 4.4). In HP- individuals, the PTPN11 A allele was the only 
factor associated with IM. However, in HP+ individuals the factors of older age 
and the NQO1 609 T allele, IL-10 819 C allele and PTPN11 A allele were all 
significantly associated with IM. These results suggest that HP status is an effect 
modifier of the association between IM and the PTPN11 A allele (P = 0.002). As 
it is possible that IM+/HP cases in this study had prior unrecorded HP infection 
(183), subgroup analysis on cases with a "revised HP+" status (either HP+/IM-, 
HP+/IM+ or HP-/IM+) was also performed. Age (OR = 2.10, 95%CI: 1.24-
3.56, P = 0.006) and IL-10 -819 C allele (OR = 1.82, 95%CI: 1.07-3.08, P =0.027) 
were the only significant variables in this subgroup. 
4.4 Discussion 
In this study, 18 polymorphisms that were previously linked to GC were 
investigated for possible associations with IM in a Singapore-Chinese population. 
The assumption was made that IM represents a precursor lesion for the 
development of GC and hence should have similar genetic risk factors. The 
cohort evaluated here was considered to be at elevated risk for GC because of 
the selection of individuals aged >50 years (123). As expected, older individuals 
and those demonstrating seropositivity for HP showed a doubling in the 
frequency of IM (Table 4.4). 
Following univariate analysis, 3 genotypes were found to be associated with IM. 
The NQO1 609 T allele was associated with IM, particularly in HP+ individuals. 
The IL-10 -819 C allele was also significantly associated with IM in HP+ cases. 
Interestingly, the PTPN11 An allele in intron 3 (rs2301756) was associated with 
76 
 
increased incidence of IM in HP- individuals but a decreased incidence in HP+ 
cases. In multivariate analysis, all 3 polymorphisms remained significantly 
associated with IM, with the exception of the NQO1 609 T allele which was 
associated with borderline significance in the overall cohort (P = 0.056). 
Previous data lends support to our observations. NQO1 (NAD(P)H: quinine 
oxidoreductase 1) codes for a cytosolic enzyme that protects cells from oxidative 
damage by preventing the generation of semiquinone free radicals and reactive 
oxygen species (184). The C to T substitution at nucleotide 609 in exon 6 results 
in a change of amino acid from Pro to Ser at codon 187 (185). Whereas the CC 
homozygous wildtype genotype (Pro/Pro) has full enzymatic activity, the TT 
genotype (Ser/Ser) completely lacks activity. The NQO1 609 TT genotype has 
been associated with an increased risk for various tumour types including 
gastrointestinal and urological cancers (186-189). An increased risk of GC in 
patients with a family history of upper gastrointestinal cancers was also reported 
for the NQO1 609 TT genotype in a study on Chinese subjects (176). Our 
observation of increased prevalence of IM in carriers of the NQO1 609 T allele 
concurs with earlier reports on its association with various cancers and can be 
explained by a decreased activity for the detoxification of environmental and 
dietary carcinogens. 
The NQO1 C609T polymorphism was previously associated with seropositivity 
to HP in a Japanese study (190), thus raising the possibility that it is an indirect 
risk factor for IM via association with HP infection. However, we found no 
association between the NQO1 C609T polymorphism and HP infection in the 
present cohort (results not shown). Carriers of the IL-10 -819 C allele express 
higher mucosal levels of IL-10 (interleukin 10) mRNA and experience 
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colonization with more virulent HP strains (191). Similar to NQO1 C609T, no 
association was observed here between the IL-10 T-819C polymorphism and HP 
infection. The current result showing the IL-10 -819 C allele is associated with 
IM is at odds with an Italian study that reported the TT genotype was associated 
with increased risk of IM (182). However, two studies in Chinese and German 
populations found no associations between IL-10 T-819C and IM (191, 192). 
Other common polymorphisms in the IL-1β and TNF-αcytokine genes have 
been proposed to influence the host response to HP and therefore the risk of 
developing GC (167, 182, 191-195). The IL-1β C-511T and IL-10 A-1082G 
polymorphisms were investigated in this cohort, but no significant associations 
were found with seropositivity to HP or with the presence of IM (Table 4.3). 
Previous studies reported the IL-1β -511 T allele increased the risk of IM in some 
(191, 192), but not all populations (166). One study found an association between 
the IL-10 A-1082G polymorphism and IM (166, 196), but 3 other studies did 
not[12,29,39]. PTPN11 (protein tyrosine phosphatase, non-receptor type 11) 
encodes for SHP-2, a protein tyrosine phosphatase thought to play a key role in 
intracellular signaling elicited by growth factors and cytokines (197). Interactions 
between the HP cagA protein and SHP-2 in gastric epithelial cells are believed to 
contribute to the development of GC (198). The PTPN11 AA genotype was 
associated with reduced risk of gastric atrophy in a Japanese population of HP 
seropositive individuals (168, 183). In those studies, the assessment of gastric 
atrophy was done with serology test (pepsinogen levels). The present results on 
IM in HP seropositive Singapore-Chinese support these earlier observations, 
although the number of AA genotype individuals (n = 6) did not allow separate 
evaluation of this group. The diagnosis of IM was based on histology 
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examination. The PTPN11 intron 3 G/A SNP may be in linkage disequilibrium 
with a coding marker that influences the interaction of SHP-2 with cagA and 
subsequent downstream signaling. However, its association with increased 
frequency of IM in HP negative individuals suggests it may play a role 
independently of this factor. 
In summary, we found 3 polymorphisms associated with IM in a Singapore-
Chinese population that was at high risk for GC because of older age and 
seropositivity for HP. The value of these SNPs in facilitating more cost-effective 




Table 4.1 PCR primers and dispensation sequences for pyrosequencing of 17 SNPs evaluated for association with IM. 
  
  PCR Pyrosequencing 
Locus  Forward Primer Reverse Primer oC bp Sequencing Primer 
Dispensatio
n 
    
IL10 – 1082 A/G  CTCAATCAAAGGATCCCCAGAGAC AGGCTGGATAGGAGGTCCCTTACT 60 253  ACACTACTAAGGCTTCTTTG cgagcagta 
IL10 – 819 T/C   GGCCAATTTAATCCAAGGTTT TCTGCACTTGCTGAAAGCTTCTTA 60 207  CCTTGTACAGGTCATGTAA gtcgatctc 
IL-1B – 511 T/C   CATGAGATTGGCTAGGGTAACAG GCCCTCCCTGTCTGTATTGA 60 230  CAATTGACAGAGAGCTCC atctgagca 
MMP2 – 1306 T/C  TTTCATCTCTGGGCCATTGT TGAAGTTCTCCCTGTGACAACC 60 265  TCCCCACCCAGCACT gctgactct 
EGF +61 A/G   GTCATCCCTGCTTTCCTGTGTG CAGAGCAAGGCAAAGGCTTAGA 60 266  CCCAATCCAAGGGTTGT cagactgac 
PTPN11 (int1) A/G  TGGACGAATGGCAAATTG GATCAATCCCACCTGAGACAGA 60 182  TTGTCTCTAAAGGACTGTG tgagctcat 
NQ01 C609T  AACTGCATGGAATTGGTTGACTTA TGGTGTCTCATCCCAAATATTCT 60 191  GTGGCTTCCAAGTCTTA cgatcgtca 
STCH rs2242661  AACTCGAATCCTGGACCTGATTAG CTGGCGTTTATAATCAAACCTGTG 65 203  GCGGAAAGAGAAAGG gctagtact 
STCH rs1882881  CTATGGAAGGCTGCGAGAAC ACTTCCAGCTACAGGCAACATT 65 213  GAGGCTTTTTCCATCA gcagtcgtg 
STCH rs12479  CTTGAAGGACCGTGTTGATGT` GCAAAGGTCTCGGATAACAAAAA 60 312  ATGTTTCAGCACCAT gatagctag 
STCH rs9982492  TCGTGCTTACCTTGTTCACATT AGTATGAGCCCTGCCATGA 60 193  CCACTTGTCCTTTAAGTCC actcgactc 
SULT1A1 G638A  GCCAGATCGCCTCTGAGGT TGGGGGACGGTGGTGTAGT 65 233  CCTGGAGTTTGTGGG tgcgagctc 
ADPRT T2285C  GATACCTAAGTCGGGGGCTTTC ACAAGCTTTCCAGGAGATCCTAAC 65 262  TGCTCCTCCAGGCCA cagtctgat 
HER2 +17ex17 A/G  GTCCCTCCCACCCCAAACTA CTGCCGTCGCTTGATGAG 65 145  CCCTCTGACGTCCAT gtcagatct 
TP53 C215G  TCCCAAGCAATGGATGATTTGA AAGCCCAGACGGAAACCGTAG 60 230  CAGAGGCTGCTCCCC tgcagtgct 
FR-a A1314G  AAGTGGAGACTGAGGCCCAGA TGACCCCTCCCCACCAAC 60 183  GTGTGGCCTGCTCAA cgagtacga 
MTHFR C677T   ACTGTCATCCCTATTGGCAGGTTA TCGGTGCATGCCTTCACAA 60 168  GAAGGTGTCTGCGGG cgagtacga 
 
 
Table 4.2 Characteristics of study subjects in relation to the presence of IM 
 
 otal (%) IM+ (%) IM- (%) 
Subjects 374 128 246 
Mean age ± SD (range) 60.5 ± 7.8 62.9 ± 7.8 59.2 ± 7.5 
Age  50-59 yrs 190 (51) 48 (38)* 142 (58)* 
Age  60-69 yrs  133 (36) 55 (43) 78 (32) 
Age  ≥70 yrs 51 (13) 25 (19) 26 (10) 
Male 207 (55) 72 (56) 135 (55) 
Family history of GC 66 (18) 23 (18) 43 (17) 
HP infection 191 (51) 84 (66)* 107 (43)* 
Drinker 66 (18) 22 (17) 46 (19) 
Smoker 90 (24) 30 (23) 60 (24) 
Chronic gastritis 290 (78) 115 (90) 175 (71) 
Atrophy gastritis 194 (52) 97 (76) 97 (39) 
Dysplasia 1 (0.3) 1 (0.8) 0 
 
* P<0.05   
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(rs number) Genotype IM- IM+
HP-  HP+ 
     IM- IM+  IM- IM+ 
ADPRT Val762Ala TT 71 31 33 9  38 22 
(rs1136410) TC 117 60 64 24  53 36 
 CC 33 16 13 6  20 10 
EGF +61A/G AA 22 5 13 1  9 4 
(rs4444903) AG 103 55 54 20  49 35 
 GG 110 58 50 18  60 40 
FR-α 1314A/G GG 164 95 74 30  90 65 
(none) GA 74 31 43 12  31 19 
 AA 6 1 5 0  1 1 
HER2 Ile/Val AA 174 92 87 32  87 60 
(rs1801200) AG 60 30 29 8  31 22 
 GG 1 1 1 1  0 0 
IL1RN 86-bp VNTR 44 212 101 112 33  100 68 
(none) 24 28 18 9 4  19 14 
 34 1 2 0 2  1 0 
 54 0 1 0 0  0 1 
 22 2 2 0 1  2 1 
IL-1β -511C/T CC 64 35 33 10  31 25 
(rs16944) CT 119 62 63 21  56 41 
 TT 48 23 20 10  28 13 
IL-10 -819T/C TT 131 55 57 21    74* 34 
(rs1800871) TC 78 46 39 15  39 31 
 CC 22 16 17 3  5 13 
IL-10 -1082A/G AA 207 100 98 37  109 63 
(rs1800896) AG 21 14 13 3  8 11 
 GG 2 0 2 0  0 0 
MMP2 -1306C/T CC 178 79 85 28  93 51 
(rs243865) CT 46 22 26 8  20 14 
 TT 3 2 2 0  1 2 
         




(rs number) Genotype IM- IM+
HP- HP+ 
     IM- IM+  IM- IM+ 
MTHFR 667C/T CC 132 77 64 23 68 54 
(rs1801133) CT 98 42 50 16 48 26 
 TT 14 7 8 2 6 5 
NQO1 609C/T CC 64* 21 27 10   37* 11 
(rs1800566) CT 143 80 78 25 65 55 
 TT 28 22 13 4 5 18 
TP53 Arg72Pro CC 45 16 22 7 23 9 
(rs1042522) CG 126 78 66 23 60 55 
 GG 51 26 24 10 27 16 
PTPN11 rs2301756 GG 175 85   92* 24   83* 61 
(rs2301756) GA 58 28 26 16 32 12 
 AA 4 2 0 1 4 1 
STCH rs12479 GG 102 58 51 20 51 38 
(rs12479) GA 106 39 52 12 54 27 
 AA 22 15 10 8 12 7 
STCH rs1882881 AA 58 34 24 13 34 21 
(rs1882881) AC 123 58 67 15 56 43 
 CC 57 31 26 13 31 18 
STCH rs2242661 AA 69 31 34 12 35 19 
(rs2242661) AG 106 46 52 13 54 33 
 GG 44 26 22 13 22 13 
STCH rs9982492 CC 85 45 41 15 44 30 
(rs9982492) CT 105 39 53 12 52 27 
 TT 28 18 14 9 14 9 
SULT1A1 638G/A GG 221 108 112 33 109 75 
(rs9282861) GA 16 10 6 6 10 4 
 AA 1 0 1 0 0 0 
 
* Bold type denotes significant difference in genotype frequencies 
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Table 4.4 Multivariate logistic regression analysis for associations with IM 
 
 OR for IM 
(95% CI) 
P 
All cases   
  HP (positive vs negative) 2.16 (1.35 - 3.45) 0.001 
  Age (>60 vs <60 yrs) 2.21 (1.40 - 3.49) 0.001 
  NO1 (CT/TT vs CC) 1.74 (0.99 - 3.06) 0.056 
HP- cases   
  Age (>60 vs <60 yrs) 1.92 (0.92 - 4.00) 0.082 
  PTPN11 (GA/AA vs GG) 2.51 (1.16 - 5.40) 0.019 
HP+ cases   
  Age (≥60 vs <60 yrs) 2.19 (1.15 - 4.17)  0.017 
  NQO1 (CT/TT vs CC) 2.61 (1.18 - 5.80) 0.018 
  IL-10 -819 (TC/CC vs TT) 2.32 (1.21 - 4.43) 0.011 
  PTPN11 (GA/AA vs GG) 0.46 (0.21 - 0.99) 0.048 
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C h a p t e r  V  
STUDY 4 - USING PEPSINOGEN AND HP ANTIBODIES TO PREDICT 
THE RISK OF GASTRIC CANCER 
 5.1 Introduction  
In Singapore, GC is the 5th most common cancer in males and 7th most common in 
females. The age standardized rate of GC for the period 2006 to 2010 is 14.3 per 
100,000 per year in Singapore Chinese males and 7.9 per 100,000 per year in 
Singapore Chinese females (199). The risk of GC incidence in Singapore is at 
intermediate level, in contrast with high incidence countries such as Japan and Korea 
and low incidence countries such as India and the United States (4). Population 
screening in Singapore is not considered to be cost-effective (117). It is therefore 
important to have an efficient and cost-effective screening method which could 
select people who are at high risk of developing GC and provide screening 
accordingly.  
It has been well established that gastric carcinogenesis begins with and progresses 
from superficial gastritis to subsequent development of atrophic gastritis, metaplasia, 
dysplasia and finally culminating in adenocarcinoma (64). Helicobacter pylori (HP) 
infection is a strong risk factor for the development of both atrophic gastritis and 
GC (9, 13, 200-202). There are broadly two divergent responses of long-term HP 
infection, namely antral-dominant gastritis with little atrophy and corpus-dominant 
gastritis with multi-focal atrophy which suggests high risk of GC (203-205). Atrophic 
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gastritis is a condition characterized by loss of glands and specialized cells in the 
stomach, and  is hence a precursor lesion of GC (64). It can be diagnosed by 
histological examination of gastric biopsies, measuring gastric maximum acid output, 
or measuring serum or plasma concentration of proteins released from the gastric 
cells, such as pepsinogens (142, 206). Pepsinogens are proteinases that are mainly 
secreted by gastric cells and are classified into two major types: pepsinogen I (PG I) 
and pepsinogen II (PG II). PG I is secreted from the gastric fundic mucosa and PG 
II is secreted from the cardiac, fundic, and antral mucosa of the stomach, as well as 
the duodenal mucosa (143, 144). A low concentration of PG I or a low PG I to PG 
II ratio (PG I : II ratio) in the serum or plasma is an indicator of atrophic gastritis 
and is associated with an elevated GC risk (207, 208).  
The combined use of plasma pepsinogen (PG) measurement and plasma HP 
antibodies has been widely used as a screening tool for GC in Japan (145, 208-210). 
Several prospective and case-control studies have shown that the HP-PG panel was 
effective at predicting the risk of GC and it could reduce the number of  subsequent 
endoscopy screening and surveillance for the early detection of GC by targeting on 
high risk group of people(11, 146, 211-213). Recently, K Miki had reviewed the latest 
results of studies and reported the current status of using HP-PG (‘ABC method’) 
for screening GC risk (214). The ‘ABC method’, a screening system proposed in 
2007, classified subjects into four risk groups and offered endoscopy screening at 
different frequencies according to the risk level of the subjects. Although the 
effectiveness of this screening method remains unknown, evidence based on 
86 
 
Japanese studies has supported the use of HP-PG as a stratification tool for GC. We 
aim to validate the ‘ABC method’ in our cohort of selected subjects in the Singapore 
Chinese Health Study. We also aim to examine the different antibodies of HP and 
their associations with GC. 
5.2 Methods 
Study population 
The subjects in this study were selected from the Singapore Chinese Health Study 
(SCHS), a prospective cohort for long-term study of dietary, genetic and 
environmental determinants of cancer and other chronic diseases. The details of the 
study design had been described in Chapter 2.  
Identification of gastric cancer cases  
Incident GC cases occurring within the Singapore Chinese Health Study cohort were 
identified through the population-based cancer registry in Singapore (215). The 
nationwide cancer registry has been in place since 1968 and has been shown to be 
comprehensive in its recording of cancer cases (215). As of 12 Dec 2010, there were 
total 650 subjects who were diagnosed with GC. 222 GC subjects donated blood 
samples. Of these, 178 cases donated blood before the occurrence of GC. After 7 
cases were excluded as they were either lymphoma or stromal tumor (GIST), 171 cases 




For each of the 171 cases, 3 control subjects were selected among the participants who 
had donated blood samples, who were still alive and free of any cancer. The controls 
were matched to the index case on age at study enrollment (±3 years), gender, dialect 
and the year blood was collected. There were 9 cases where only 2 eligible controls 
were found. The study consists of 171 cases and 504 controls. 
Blood tests (HP and PG) 
HP antibodies were measured by Western Blot Assay (Helico Blot 2.1, MP 
Biomedicals, Singapore), a qualitative assay for the detection of IgG antibodies to HP 
in human serum or plasma. After individual strips were incubated with diluted serum 
or plasma specimens, specific antibodies to the various antigens, if present, bound to 
the HP antigens on the strips. This allowed differentiation of reactivity to each of the 
various HP antigens including CagA, VacA, UreA etc. HP seropositivity was 
determined by the recommended criteria designed by the manufacturer, which is any 
one of the following conditions: 1) 116kD (CagA) positive, where CagA has to be 
present with one or more of the following bands: 89kD (VacA), 37kD, 35kD, 30kD 
(UreA), 19.5kD, or with current infection marker. 2) Presence of any one band at 
89kD, 37kD or 35kd, with or without current infection marker. 3) Presence of both 
30kD and 19.5kD with or without current infection marker. Through validation 
against histology, culture, rapid urease test and/or urea breath test (UBT), the 
sensitivity and specificity reported in the protocol of the kit by the manufacture is 96% 
and 95% respectively.  
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PG I and II were measured by using latex agglination turbidimetric immunoassay kit 
(LZ Test “Eiken” Pepsinogen I and II, Tokyo, Japan) and automated analyzer 
(Siemens Advia 2400). Results were defined as “atrophic gastritis” if PG I level was < 
70 ng/ml and PG ratio was < 3, as recommended by manufacture. This criteria has 
been used widely in the mass screening for GC in Japan.  
All measurement was done by lab personnel blinded to the case/control status and the 
samples were analysed in a set of 4 (one case and three controls) or 3 (one case and 
two controls).  
Statistical analysis 
The chi-square test and the Student's t-test were used to compare the distributions of 
selected demographic, lifestyle and dietary factors between cases and controls. The 
distributions of blood markers measured were markedly skewed with a long tail toward 
high values, which were corrected, to a large extent, by transforming the original values 
to logarithmic values. Therefore, geometric (as opposed to arithmetic) means are 
presented to minimize the effect of high values. The conditional logistic regression 
method was used to examine the associations between plasma markers measured and 
risk of GC. Statistical computing was carried out using SAS version 9.2. The statistical 
significance level was set at two-sided P value of 0.05. 
5.3 Results 
Compared to control cases, a higher percentage in the GC group had family history of 
GC, or had primary school education and below. Except for these statistically 
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significant differences, baseline characteristics were similar across both groups (Table 
5.1).  The median time interval between the baseline interview and GC diagnosis was 
11 years (range: 1 -17 years). The mean time interval from blood collection to the 
diagnosis of cancer was 4.3 (SD 2.9) years.  
The mean values of PG I and PG ratio were significantly lower in cases than in 
controls (P < 0.0001 for both). PG II was slightly higher in cases (P = 0.045) (Table 
5.3). Of 171 cases, 61 were positive for atrophic gastritis according to manufacturer’s 
criteria (PG I < 70 ng/ml and PG ratio < 3); 68 out of 504 controls were positive for 
atrophic gastritis.  
Six HP antibodies (CagA, VacA, UreA, 35kD, 37kD and 19.5kD) were individually 
associated with GC, with statistically significantly increased ORs after adjustment for 
multiple potential confounding factors. The ORs (95% CI) of CagA, VacA, UreA, 
35kD, 37kD and 19.5kD for the risk of GC were 5.82 (2.22-15.27), 4.17 (2.14-8.12), 
2.81 (1.64-4.81), 2.06 (1.40-3.01), 2.46 (1.62-3.73) and 1.87 (1.27-2.77) (Table 5.3). The 
overall HP seropositivity based on the manufacturer’s recommendation was also 
associated with increased risk of GC with OR (95% CI) 5.11 (2.14-12.22).  Subjects 
with atrophic gastritis as determined by PG index had 4.02 times the GC risk of those 
without atrophic gastritis (95% CI 2.56-6.30).  
Subjects were classified into three groups based on positivity of HP CagA antibody 
and PG index (Table 5.4). Group A (HP-/PG-) was considered as low risk group with 
negative for CagA and negative PG index. Group B (HP+/PG-) continued with 
negative PG index but positive CagA antibody. Group C (HP+/PG+) had positive 
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PG index with positive CagA antibody. There was no subject who had positive PG 
index but negative for HP CagA antibody. The adjusted ORs were calculated in each 
group. Risk of GC increased from A to C with group C having the highest ORs. Using 
the group A as reference group, the ORs (95% CI) for group B, C were 4.02 (1.51-
10.73), 13.95 (5.01-38.87) respectively.  
5.4 Discussion 
Our study is the first outside Japan to investigate the association between the 
combination of plasma PG and HP antibodies and the risk of GC in a Chinese 
population recruited from the community. A few prospective studies had been done in 
Japan (146, 211). A study based on the Shanghai Women Cohort (10) demonstrated 
that low PG ratio was associated with higher risk of GC but HP was not found to be 
significantly associated with the risk of GC due to the high prevalence of HP in both 
case group and control group. Our study is more representative of the general 
population because it was not limited by gender.  
The results from our study are consistent with one case-control study in Japan (11) and 
showed that serum PG index and HP antibodies were able to stratify the study 
population into groups with low risk (group A), intermediate risk (group B) and high 
risk (group C) of developing GC.  There were no subjects who had PG index positive 
without HP infection. In prospective studies from Japan, subjects who had atrophic 
gastritis determined by PG index without HP infection were considered to be at very 
high risk with about 15-30 times higher risk than the low risk group (146, 211, 213). 
The high risk group C comprising subjects with atrophic gastritis and positive for 
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CagA had 13.95 times higher risk of getting GC, compared to low risk group A who 
were negative for HP antibodies and without atrophic gastritis. The ORs increased 
steadily from group A to group C.  The atrophic gastritis indicated by the PG level was 
strongly associated with increased risk of GC. The persistent chronic inflammation 
was found to play an important role in initiation and promotion of cancer 
development (216). Atrophic gastritis was the result of chronic (long term) 
inflammation in stomach. Two mechanisms of how chronic gastritis initiates gene 
mutation were suggested. In a mouse model of HP-induced GC, bone-marrow stem 
cells were found in the stomach epithelium in chronic inflammation environment and 
underwent malignant progression which gave rise to gastric tumor (217). Another way 
is the high concentration of free radicals due to the excessive demand of oxygen in the 
chronic inflammation, leading to subsequent DNA damage. As the result, tissue stem 
cells were mutated and cancer development was initialized (218).   
Amongst 675 subjects, 12% was in group A, 69% was in intermediate group (group B), 
19% was in group C (high risk). A possible reason for the high percentage in 
intermediate group and low percentage in group A is that our study population 
contains elderly Chinese who are more likely to be HP positive compared to the 
general population. A second possible reason is a relatively high ratio of GC to 
controls in this nested case-control study. We propose both low risk group and 
intermediate group (81% of the total population) could be exempted from frequent 
endoscopic surveillance in countries with intermediate level of GC risk. Similar 
recommendation has been made in a prospective study in Japan where the annual 
incidence of GC in males over 60 years old in group with HP+/PG- (0.4%) was 
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similar to that in group with HP-/PG- (0.3%) (146). In comparison, the GC incidence 
in group with HP+/PG+ (1.0%) was much higher than group with HP+-/PG-. It 
seems HP status does not significantly affect the risk of GC in people who are negative 
for PG index. Risk stratification based on non-invasive blood test enables targeted 
endoscopic screening in people who are at high risk of GC.  
In addition, we found that HP antibodies CagA, VacA, UreA, 35kD, 37kD and 
19.5kD were all significantly associated with increased risk of GC with ORs which lies 
within the range 1.87 – 5.82. Among them, CagA had the highest OR and was the 
most sensitive antibody with the prevalence of 97% in cancer group. Many studies had 
evaluated CagA which was believed to be related to higher degree of gastric 
inflammation and higher risk of GC (27, 219).  We found that by using CagA alone we 
were able to indicate the HP infection status and best predict the GC risk.  
There are a few strengths in our study. Subjects were recruited from the community 
and the subjects were asymptomatic at the enrolment and had been observed for long 
term. The two prospective studies from Japan (146, 211) recruited subjects who were 
undergoing health screening or from a special workplace and the potential selection 
bias had to be taken into consideration when we interpreted the result. The 1:3 ratio of 
case/control maximized statistical power. Blood samples in our study were collected 
before cancer was diagnosed to minimize the potential influence from disease 
development and subsequent treatment.  
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Cardia GC, which have been suggested to have little association with HP, were not 
subjected to stratification analysis here because of lack of information, similarly for 
intestinal type and diffuse type GC.  
In summary, the HP-PG panel was able to predict the risk of GC in our population. 
The OR of the high risk group (atrophic gastritis with HP CagA seropositive) was 
13.95 compared with the low risk group where both atrophy gastritis determined by 
PG index and HP were negative. The study indicated the HP-PG panel was useful to 
stratify the population into low and high risk group. In order to justify risk-stratified 
screening at national level, future prevention study on GC using HP-PG panel in 
Singapore’s general population is required. In addition, we found that CagA alone was 




Table 5.1 Baseline characteristics of case and control subject 
 
 Case (n=171) Control 
(n=504) 
P value  
Age at blood draw 66.6 (7.6) 66.4 (7.4) 0.749 
Male (%) 113 (66.1) 334 (66.3) 0.964 
Education (%) 
None 45 (26.3) 115 (22.8) 0.025 
Primary 96 (56.1) 248 (49.2)
Secondary and above 30 (17.5) 141 (28.0)
Smoking status 
Never 92 (53.8) 285 (56.6) 0.712 
Former 28 (16.4) 85 (16.8)
Current 51 (29.8) 134 (26.6)
Alcohol drinking 
None-monthly 140 (81.9) 438 (86.9) 0.264 
Weekly 24 (14.0) 50 (9.9)
Daily 7 (4.1) 16 (3.2)
Family history of gastric 
cancer 
7 (4.1) 5 (1.0) 0.008 
Body mass index 23.2 (3.2) 23.2 (3.2) 0.918 
Total vegetables intake 
(g/day)  
113.5 (64.9) 110.2 (60.9) 0.551 
Total fruit intake  (g/day) 201.0 (188.7) 208.4 (161.8) 0.649 









2-sided P * 
PGI # 38.67 (2.3) 52.78 (1.8) <0.0001 
PGII # 13.06 (1.9) 11.81 (1.8) 0.045 
PG ratio 2.97 (1.9) 4.47 (1.7) <0.0001 
 
# The unit of PGI and PGII is ng/ml  




Table 5.3 Adjusted ORs of GC risk with HP antibodies or PG index alone 






Adjusted ORs * 
(95% CI) 
Cag A  
Negative 6 (3.5) 73 (14.5)    1.00
Positive 165 (96.5) 431 (85.5)  5.82 (2.22-15.27) 
VacA 
Negative 13 (7.6) 117 (23.2)   1.00
Positive 158 (92.4) 387 (76.8)  4.17 (2.14-8.12) 
UreA 
Negative 20 (11.7) 128 (25.4)   1.00
Positive 151 (88.3) 376 (74.6)  2.81 (1.64-4.81)   
19.5 kD 
Negative 58 (33.9) 239 (47.4)   1.00
Positive 113 (66.1) 265 (52.6)   1.87 (1.27-2.77)   
35 kD 
Negative 70 (40.9) 284 (56.3)   1.00
Positive 101 (59.1) 220 (43.7)   2.06 (1.40-3.01)   
37 kD 
Negative 56 (32.7) 253 (50.2)   1.00
Positive 115 (67.3) 251 (49.8)   2.46 (1.62-3.73)   
PG index 
Negative 110 (64.3) 436 (86.5)   1.00
Positive 61 (35.7) 68 (13.5)   4.02 (2.56-6.30) 
HP positivity ** 
Negative 8 (4.7) 84 (16.7)    1.00
Positive 163 (95.3) 420 (83.3)  5.11 (2.14-12.22)  
 
* Adjust for education, smoking, alcohol, BMI, sodium, vegetables, 
fruits 








Adjust for education (D5_2_2), smoking (D14_1), alcohol (D37_1_2), BMI (D2_2), 
sodium (N3_14), vegetables (F3_6), fruits (F3_7) 







Group B Group C 
PG index  Negative  Negative  Positive 
CagA Negative  Positive  Positive 
Controls 73 (14.5) 363 (72.0) 68 (13.5) 
Cases  6 (3.5) 104 (60.8) 61 (35.7) 
OR (95% CI) 1.00 4.02 (1.51-10.73) 13.95 (5.01-38.87) 
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C h a p t e r  V I  
CONCLUSION AND FUTURE STUDIES 
The development of GC is a multifactorial and multistep process. So far, there is no 
effective prevention programme to reduce the incidence of GC. Screening and early 
detection is still the key strategy to improve GC-related mortality. The successful 
screening experience in Japan has suggested that screening will help reduce GC 
mortality rate if we can target the high risk group in a country like Singapore where the 
incidence rate is at intermediate level. 
In this thesis, we made use of two Singapore Chinese cohort studies – GCEP and 
SCHS – to investigate gene polymorphisms and the use of the blood marker HP-PG 
panel in GC risk stratification. This allows us to use immediately available data and 
biological samples to achieve sufficient statistical power to detect real association. It 
will also make possible the validation of other biomarker for GC risk stratification or 
early detection; similarly, for future gene-environmental interaction studies. Through 
genotyping of blood samples from GCEP subjects, we were able to investigate the 
genetic factors associated with increased risk of IM, a precursor lesion of GC.  
In study one, we described the baseline characteristics of the GCEP cohort study and 
investigated the feasibility of endoscopic surveillance in the high risk group. The results 
look positive. All 18 early gastric neoplasia detected in the programme were in stage 0 
or stage I. It seemed that endoscopic surveillance with frequency of two years was able 
to detect the GC at early stage. As the study is still ongoing, we expect more conclusive 
99 
 
suggestions on surveillance frequency, and recommendations on how often we should 
follow up with those people with precursor lesions could be drawn after year 2015 
when all subjects complete at least 5 years surveillance. One limitation we have to 
highlight here is that the study recruited from amongst patients attending the 
gastroenterology clinic, a targeted population which is known to be at higher risk of 
developing GC. This should be taken into consideration during interpretation of the 
result, especially from the perspective of application in the general population.  
In study two, we examined the clinical risk factors as well as the premalignant lesions 
of GC in the risk of developing GC. With 18 gastric neoplasia cases detected in GCEP 
cohort, we found that age over 70 years old, primary education or below, smoking, 
atrophic gastritis and IM were statistically significantly associated with early gastric 
neoplasia. These risk factors may not be conclusive at the moment as we have not 
completed the 5 years surveillance for all subjects. The HRs of five risk factors 
mentioned in the study were between 2.72 - 8.01 and it suggested the results were 
unlikely to be due to chance. Subjects with IM lesions alone had 8 times high risk of 
GC compared with those who are negative for IM. Surveillance endoscopy should be 
considered for these IM subjects.  
In study three, we aimed to identify the genetic factors which could help in risk 
stratification. Three polymorphisms NQO1, IL-10 and PTPN11, in combination with 
HP status, were found to be associated with the increased risk of IM and could be 
used to identify individuals who are more likely to develop IM and therefore GC. 
Based on literature search, it is difficult to use gene polymorphism in risk stratification 
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because of inconsistent result in case-control studies thus far. However, some 
promising results were seen from next genome sequencing (NGS) studies and genome 
wide association studies (GWAS). ARID1A gene (a tumor suppress gene) mutation 
was found in two NGS studies. Prostate stem cell antigen (PSCA) gene 
polymorphism and PLCE1 (encoding phospholipase Cε1) were also found to be 
associated with susceptibility of GC. Based on results from NGS and GWAS, the 
candidate gene approach could be carried out to identify the specific SNP in predicting 
GC risk by taking into consideration the subject’s race and HP status. Validation using 
a large cohort study to identify the SNPs associated with intestinal type, diffuse type or 
cardia GC or non-cardia GC should also be done before the results can be used in 
clinic. 
In study four, the first study of its kind outside Japan, we validated the HP-PG panel 
in a Singapore Chinese elder population. The results showed that risk of GC increased 
from group A (HP-/PG-) to group B (HP+/PG-) and group C (HP+/PG+) with 
group C having the highest OR. Using the group A as reference group, the ORs (95% 
CI) for group B, C were 4.02 (1.51-10.73), 13.95 (5.01-38.87) respectively. This proved 
that the HP-PG panel was able to stratify subjects into low, moderate and high risk 
groups. There are some limitations with the use of the HP-PG panel. First of all, HP-
PG stratification was based on assumption that GC carcinogenesis was initialized by 
chronic gastritis and progressed to atrophy gastritis, IM, dysplasia and eventually 
became GC. So the result was only able to pick up intestinal type GC. The HP-PG 
panel may not be able to stratify risk of other types of GC such as diffuse type or GC 
in cardia location. More risk factors for each type of GC will be identified in 
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prospective cohort. Genetic factors are believed to be significant in development of 
diffuse type GC. It is important to combine the HP-PG panel together with gene 
mutation candidate or gene polymorphism which is associated with GC risk in order to 
identify all subjects who are at high risk of GC. Secondly, the HP-PG panel should be 
validated in a prospective study such as the GCEP study.  
Collectively, we have found that endoscopic surveillance was feasible for early 
detection of gastric neoplasia and five risk factors were confirmed in Singapore 
Chinese high risk cohort. Using three gene polymorphisms can help identify people 
associated with increased risk of IM and therefore GC. HP-PG panel was effective in 
risk stratification for GC which was consistent with the results from Japan. In future, 
we expect more studies to be performed in the following four areas: 
First, a large scale prospective study recruiting subjects from the general population 
should be carried out in order to validate findings related to biomarkers for either GC 
risk prediction or host susceptibility. The study should include dietary factors which 
are important in GC development. These dietary factors include salt intake, fruit and 
vegetable intake, nitrate or nitrosamine in processed meat et al. The collection of 
dietary factors is complicated and requires large amount of resources because of wide 
range of food items, various cooking method and different sauces used in dialect 
groups.  Standardization of the estimation of food intake is required when quantifying 
the amount of specific food ate.  Data collected on dietary factors can only reflect the 
most recent status of food intake. Long term recall of food intake is not feasible and 
some justifications are required when the subject is immigrant or there is change of 
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cooking style et al. This large scale study should also have enough power to detect the 
risk factor with small OR and be able to investigate the possible gene-environmental 
interactions.  
Secondly, we need more biological functional studies on genes found to be associated 
with GC risk based on NGS or GWAS studies. This will help us understand the effect 
of gene mutation or gene polymorphism and contribute to our understanding of GC 
carcinogenesis. Those studies could be in vitro or in animal model. Validation or meta-
analysis of the panel of gene polymorphisms which can predict host susceptibility is 
needed, before they can be applied in the clinic. The validation study should also take 
into consideration of intestinal and diffuse type of GC. The findings on risk 
stratification in this thesis focused on intestinal type GC. Using genetic markers to 
identify people who are at high risk for diffuse type GC may help improve the 
screening strategy.  One study had reported CDH1 mutation screening in 43 families 
with hereditary diffuse GC and 30% of the families were found to have CDH1 
mutation (67). The results should also be reproducible in different populations with 
different study designs. As there are only 300 new GC cases in Singapore  per year, this 
kind of validation study should combine GC cases from similar studies in other 
countries in order to have conclusive results.  
Thirdly, it is well known that people with IM are at high risk of GC and the prevalence 
of IM is about 50% in GCEP cohort. Although we observed that IM positive subjects 
had 8 times higher risk of GC compared with IM negative subjects, only 0.9% of IM 
positive subjects had GC. There were a large number of subjects who had IM but did 
103 
 
not progress into GC. The studies had shown incomplete IM represented by brush 
border cells and goblet cells was associated with increased risk of GC compared with 
complete IM represented by hybrid intermediate nongoblet mucous columnar cells 
with cytoplasmic drops of different size. It will be interesting to find out the other 
clinical characteristics or genetic effect modifiers in the progression from IM to GC.   
Fourthly, early GC or high grade dysplasia is difficult to diagnose and new endoscopic 
image techniques are required to improve the sensitivity of conventional endoscopy. In 
GCEP cohort, out of 18 early gastric neoplasia including high grade dysplasia and early 
stage GC, three subjects with high grade dysplasia had had endoscopy done 6 months 
or less prior to diagnosis of gastric neoplasia . This indicated that high grade dysplasia 
may have been missed at the previous endoscopy.  Projects on biomarker discovery 
for GC early detection will also be useful. GC specific miRNA panel or DNA 
methylation markers could help identify suspected GC cases and a comprehensive 
endoscopy checkup will be offered to confirm the GC.  
Lastly, a targeted screening study based on known risk factors at community level 
should be started. The aim is to determine if targeted screening reduces the mortality 
rate and the difference in incidence rate among groups with various risk level of 
developing early gastric neoplasia. Subjects will be divided according to the number of 
risk factors they have. In the low risk group with no risk factor or with some risk 
factors but the low ORs, no intervention is required. In the intermediate risk group, 
endoscopy surveillance every 5 years may be indicated. Frequent endoscopy 
surveillance with 2-3 years interval should be considered in the high risk group. With 
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the histology result from surveillance endoscopy, the subjects will be further stratified.  
The cost-effectiveness of screening based on risk stratification could also be evaluated.  
Risk stratification and targeted screening will be the trend for GC prevention due to 
the decline of GC incidence worldwide. The results from this thesis have identified 
five risk factors which are associated with early gastric neoplasia. Using these five risk 
factors together with HP-PG panel and gene polymorphism markers, we are able to 
stratify Singapore Chinese into low, intermediate and high risk for GC. If validated, 
this will give a possible solution to reduce the mortality rate in Chinese community 
where incidence rate of GC is at intermediate level. Risk stratification before 
population screening could also be similarly applied in the prevention of other 
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